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Abstract
The Ras superfamily of small G proteins are involved in cell-signaling processes that, if not
regulated, may lead to cell multiplication, apoptosis inhibition, and tumorigenesis. They function
as molecular switches, which through GTP/GDP exchange cycle, switch on or off cellular
activities. Overexpression and/or hyperactivity of these proteins have been linked to many
diseases including various cancers. CDC42, a member of the Rho subfamily of the Ras
superfamily of small G proteins, participates in the regulation of many cellular processes
including cell adhesion, mitosis, and cytoskeletal rearrangements. CDC42 binds to and activates
many effector proteins including CDC42-activated kinase (ACK). Abnormal activities of
CDC42/ACK have been associated with tumor development. It is paramount that small molecule
inhibitors be developed to inhibit CDC42 interactions with its effector proteins leading to
abnormal signaling activities. A small molecule, ZCL278, has been shown to interact with
CDC42 and alter CDC42-stimulated overactivity. In this current work, we investigated the
influence of ZCL278 on CDC42 wild type and CDC42F28L mutant as well as its influence on
CDC42/ACK protein-protein interactions. Our In vitro binding assay data suggest that ZCL278
decreased binding capacity of CDC42 to ACK. ZCL278 was shown to lower the affinity of
CDC42 for ACK by a nanomolar-to-micromolar jump in an extrinsic fluorescence titration
experiment. Isothermal titration calorimetry experiments data showed that in absence of
ZCL278, CDC42 bound to ACK with an apparent Kd value of 0.6 μM while in the presence of
ZCL278 the apparent Kd peaked to 4 μM. Overall, our binding experiments suggested that 1)
ZCL278 decreased the binding affinity of CDC42 to ACK, 2) ZCL278 bound to both CDC42
and CDC42F28L with micromolar affinity, 3) ZCL278 induced structural modifications in
CDC42 and CDC42F28L upon binding, and 4) ZCL278 rendered CDC42 and CDC42F28L more
thermally stable.
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CHAPTER ONE
Introduction
Ras Superfamily: function, structure, and division
The Ras superfamily are small guanosine triphosphatases (GTPases). They encompass more than
150 members of which the Ras proteins are the founding family [1]. They function as binary
membrane-anchored timing switches cycling between an active and an inactive conformation. In
the active conformation, these proteins switch on cell processes and switch them off in the
inactive conformation [1] (figure 1); when active, Ras superfamily are bound to GTP (Ras-GTP)
and bound to GDP (Ras-GDP) when inactive. The conversion from the GDP- to GTP-bound
conformations (and vice versa) is assisted by regulatory proteins such as guanine nucleotide
exchange factors (GEFs), GTPase-activating proteins (GAPs), and guanosine dissociation
inhibitors (GDIs) [2]. GEFs help to convert GDP-bound to GTP-bound Ras, while GAPs reverse
this process by converting Ras-GTP back to Ras-GDP [2]. GDIs bind to GDP-bound Ras and
keep them in the inactive conformation by preventing GDP/GTP exchange and their migration
toward the cell membrane [2].

Fig.1. Cycle of Ras proteins. The cycle is regulated by GDIs which keep the Ras proteins in
their inactive state and protect them upon synthesis. GEFs and GAPs activate and
deactivate Ras proteins by enhancing their intrinsic nucleotide exchange and GTP
hydrolysis capacity, respectively.
1

Ras superfamily cover more than 150 members of which Ras proteins are the founding family
[3]. They are ubiquitously expressed in all eukaryotes [3]; they are found in mammals, plants,
birds, insects, fungi, and yeast [4]. Based on sequence homology, they are divided into five
families: Ras, Rho, Rab, Ran, Arf, and Rheb [3]. Beginning at the N-terminus, Ras superfamily
have in common a set of five conserved GDP/GTP binding motif components [5] (figure 2).
These binding motif components are: G1, GXXXXGKS/T; G2, T; G3, DXXGQ/H/T; G4,
T/NKXD; and G5, C/SAK/L/T. Altogether, they constitute a ~20 KDa G domain, also called
GTP-binding domain, that is conserved throughout the entire Ras superfamily [5]. This domain
comprises five α-helices (A1–A5), six β-strands (B1–B6) and five loops (G1–G5) with G2 loop
corresponding to switch I, G3 loop corresponding to switch II (figure 2). The G1 loop is found
between the B1 strand and A1 helix with the motif X1X1X1GXXXXGK (S/T), where X1 can be
leucine (L), valine (V) and isoleucine (I), and X can be any amino acid which lodges the α- and
β- phosphate groups [6]. The G2 loop contains a conserved threonine that links the A1 helix and
the B2 strand. This loop brings about the binding of Mg2+ through conserved amino acid
residues. The G3 loop is found at the N-terminus of the A2 helix with the motif XXXXDXXGX.
Its principal role is to bind Mg2+ and the γ-phosphate of GTP or GDP. The G4 loop comprises
the motif XXX (G/A) (T/N) KXD and the G5 loop brings about the identification of the guanine
base (figure 2).
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Fig.2. Ras functional domains.
The Ras superfamily of proteins show a high level of affinity for GDP and GTP; they exchange
GDP with GTP and hydrolyze GTP to GDP at very slow speed [2]. Consequently, regulatory
proteins such as GEFs and GAPs task to increase the rate of GDP/GTP exchange and GTP
hydrolysis, respectively, to meet the requirements for fast reactions under physiological
conditions [2]. In the same branch, small GTPases have similar and different GAPs and GEFs,
whereas withing different branches they have structurally unique and mechanistically analogous
GAPs and GEFs. Ras-GDP and Ras-GTP have similar structural conformations but show major
structural differences in the switch I (residues 32-38) and switch II (59-67) regions. Ras-GTP
show high level affinity for effector proteins.
The conformational modifications of the small GTPases allow them to be recognized by effector
and regulatory proteins in their active state (Ras-GTP) and inactive state Ras (Ras-GDP) and
bind them as a result. The switch I, found at the core effector domain, is crucial in direct binding
to effector proteins. Small GTPases have been shown using a loaded-spring mechanism when
binding to effector proteins [6]. A key hallmark of Ras superfamily is their post-translational
modifications by lipids for translocation to the membrane [7] (figure 3). Effector proteins like
GEFs and GAPs switch Ras on and off upon being recruited to inner membrane and positioned
3

in the vicinity of the Ras proteins where the GTP concentration is tenfold compared to that of the
GDP. These lipid modifications include farnesyl and geranylgeranyl isoprenoid for most Ras and
Rho proteins whose N-terminal contains the tetrapeptide motif CAAX (C for cysteine, A for
aliphatic, X for any amino acid). This motif is the recognition sequence for farnesyltransferase
and geranylgeranyltransferase I. These enzymes catalyze the covalent attachment of a farnesyl or
geranylgeranyl isoprenoid, respectively, to the cysteine residue of the tetrapeptide motif. Rab
proteins have C-terminal motifs such as CC, CXC, CCX, CCXX, or CCXXX with C for
cysteine. These C-terminal motifs serve as recognition sequence for geranylgeranyltransferase II,
which also catalyzes the addition of geranylgeranyl group [8]. Some Arf proteins have their Ntermini modified by a myristate fatty acid. These modifications are paramount to the promotion
of Ras proteins attachment to the cell inner membrane and their subcellular localization, which is
key to fulfilling their biological functions [9]. While some members of the Ras superfamily do
not undergo lipid modifications but are anchored to the membranes, some are neither lipid
modified, nor membrane anchored [10].

Fig.3. Ras proteins membrane-anchored lipid modifications. These modifications, mostly of
lipidic nature, act as localization signaling sequence for a distinct Ras-like protein family.
4

Ras proteins are involved in numerous signaling transduction pathways. A well-studied Ras
signaling pathway is the activation of Ras proteins by epidermal growth factor tyrosine kinase
via the RasGEFSos [9]. Arf (ADP-ribosylation factor) and Reb (Ras-like proteins in the brain)
proteins oversee gathering, piling, and targeting vesicles to the correct cellular locations. Arf
proteins encompass up to 30 proteins with Arf1 being the most studied [10]. Arf-GTP binds to
effector proteins including vesicle coat proteins [10]. Conformational discrepancies between the
GDP- and GTP bound states bring about multiple changes in switch I and II regions and in the
N-terminal region that facilitates the myristate moiety to interconnect with membranes in their
active state. Reb proteins represent the largest family with up to 61 members [11]. Reb proteins
regulate vesicle formation, movement, fusion, and vesicular cargo transport. They are found in
distinct intracellular compartments according to their function in specific vesicle transport
activities [12]. Reb proteins location depends on prenylation, and the various C-terminal
sequences dictate their specificity [13].
Ran (Ras-like nuclear) proteins participate in the nucleus-cytoplasm transport of RNA and
proteins; they are the most abundant Ras-related proteins in the cell [14]. Unlike other families of
small proteins, Ran proteins activities are contingent on a Ran-GTP gradient [14]. Nuclear RanGTP binds to importin to bring about cargo delivery and binds to exportin-complexed cargo to
facilitate cargo export [15]. The Rho proteins represent key modulators of actin restructuring
[15]. Consequently, they participate in cell migration, wound healing, cell adhesion, cell polarity,
membrane trafficking, and cytokinesis [15]. Rho proteins are greatly conserved in the entire
eucaryotic kingdom. Among the 20 members identified the most notable and well-known are
RhoA, Rac1, and CDC42 [16].

5

Rho proteins: functions, structure, regulation, divisions, and diseases
Rho proteins are characterized by the existence of a Rho GTPase-like domain [17]. Rho proteins
are distinguished from other small GTPases by the structural component called the “Rho insert
domain” found in between the fifth β-strand and the fourth α-helix in the small GTPase domain
[17]. Typically, most Rho proteins are small (190-260 amino acids) and contain only a GTPase
domain and short N- and C-terminal elongations. In the GTPase domain, they have about 30%
amino acid sequence identity with Ras proteins and 40-95% sequence identity within the same
family [20]. All Rho proteins have the sequence motif typically found in all GTP-binding
proteins; they bind to GDP and GTP with great affinity; they cycle back and forth between
active, GTP-bound and inactive, GDP-bound states. Moreover, most members are lipid modified
at C-terminus post-translationally (figure 3). In conjunction with other C-terminal changes, the
addition of the terminal lipids assists in their subcellular localization and anchorage to specific
membranes, which is paramount for carrying out their functions.
Function-related information on Rho proteins has mostly stemmed from research conducted on
RhoA, Rac1 and CDC42. They all share the growth-promoting and anti-apoptotic roles; they are
also involved in the regulation of gene expression via the activation of molecular signals such as
serum response factor, NF-κB, the stress-activated protein kinases and cyclin D1 [18,19]. All
three work in unison to facilitate actin cytoskeleton reorganization; however, they have unique
effects on cell shape and movement [20,21]. RhoA functions as a promotor of actin-myosin
contractility and, consequently, the development of stress fibers and focal adhesions which
regulate cell shape, anchorage, and motility. Rac1 facilitates actin polymerization and
lamellipodia formation.
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CDC42 promotes the formation of thin, finger-like cytoplasmic elongations called filopodia
which consist of tight actin bundles and might participate in the recognition of the extracellular
stimuli from the environment.
Like other Ras protein, the GDP- and GTP-bound conformations of the Rho proteins structurally
vary mainly in two regions, switch I and II; this characteristic probably exists in all Rho
proteins[22]. The conformational structure of the GTP-bound Rho proteins leads to an increase
in the binding affinity for downstream effector proteins. Each Rho protein can recognize several
effectors, and some effector proteins are recognized by several family members. Rho proteins
interaction with downstream effectors regulates signaling pathways that control the many
functions of Rho proteins. The great number of effectors identified for RhoA, Rac1, CDC42 and
other family members underlines the functional complexity and diversity of these small GTPases
[23].
The Rho family of proteins
Based on their amino acid sequence identity, structural motifs and biological roles, Rho proteins
can be divided into six subfamilies that show close but distinguishable properties: 1) the RhoArelated subfamily (RhoA, RhoB and RhoC), 2) the Rac1-related subfamily Rac1 (and its splice
variant Rac1b), Rac2, Rac3 and RhoG, 3) the CDC42-related subfamily CDC42 (and its brainspecific C-terminal splice variant G25K), TC10, TCL, Chp/Wrch-2 and Wrch-1, 4) the Rnd
subfamily (Rnd1, Rnd2, and RhoE/Rnd3), 5) the RhoBTB subfamily, 6) the recently described
Miro subfamily. Moreover, RhoD, Rif and TTF/RhoH do not belong to any of these subfamilies.
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Rho-related proteins
RhoA, RhoB and RhoC show up to 85% amino acid sequence identity. They are all reported to
participate in actin-myosin contractility and to interact with similar guanine nucleotide exchange
factors (GEFs) and effectors. Nonetheless, they have several functional distinct differences
which are likely largely due to the difference in their C-terminal last 15 amino acids, which
control subcellular membrane anchorage. RhoA is found in the cytosol and to a certain extent
attached to the plasma membrane; RhoB is anchored to the plasma membrane and
endomembrane vesicles; RhoC is found in the cytosol and attached to perinuclear structures [2426].
RhoB [27] differs from RhoA and is also subject to transcriptional regulation. RhoB mRNA and
protein are stable and are upregulated by growth factors during mitosis G1 and S phases, which
hints that RhoB participates in cell proliferation [28,29]. The prenyl group can be added to RhoB
by either a geranylgeranyl or a farnesyl isoprenoid group and can be further modified by the
palmitate fatty acid (fig. 3) [30].
In contrast to RhoA and RhoC, RhoB appears to have a growth-inhibitory effect [31,32]. It has
been reported that the expression of RhoB is downregulated in tumors [33].
RhoC [34] has as well been linked to tumorigenesis. It is overexpressed in malignant pancreatic
ductal carcinomas [35], inflammatory breast cancer tumors, and highly metastatic melanomas
[36]. “Ectopic overexpression” of RhoC augments tumorgenicity and metastatic properties of
tumor progenitor cells [35,36].
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Furthermore, RhoC stimulates the expression of angiogenic factors in human mammary
epithelial cells [35], which may promote tumor vascularization. Nonetheless, activated RhoC
does not cause NIH 3T3 mouse fibroblasts transformation [37].
It has also been found that a GEF that binds to RhoA and RhoB but not to RhoC [38], and it has
been reported that RhoC interacts better with Rho kinase, an important effector for the RhoA
proteins, than does RhoA [39].
Rac1-related proteins
The entire Rac-related proteins family induces lamellipodia and membrane ruffles formation by
interacting with the PIR121-Nap125-HSPC300-WAVE complex [40]. Rac1, Rac2 and Rac3
share up to 88% of sequence identity. These three subfamilies differ mainly in the C-terminal 15
residues. Rac1b, a splice variant of Rac1, brought about by alternative splicing, has an additional
19-residue segment located C-terminal to the switch II region.
Rac1b, majorly expressed in breast and colon cancers [41,42], has an enhanced intrinsic guanine
nucleotide exchange rate and a diminished intrinsic GTPase activity [43,44]. Rac1b cannot bind
to Rho guanine nucleotide dissociation inhibitor (RhoGDI) and displays, as result, increased
attachment to the plasma membrane [44]. However, Rac1b is not capable of activating the JNK
stress-activated kinase; however, it keeps the capacity to activate the NF-κB transcription factor
[44].
Rac1 is ubiquitously expressed while Rac2 is expressed merely in hematopoietic cells, where it
appears to have specified roles [45]. Decreased expression of Rac1 leads to embryonic mortality
[46], while a lack of Rac2 leads to hematopoietic cell defects in mice but sustains a normal
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development [47]. Downregulated, deleted, or inactivated Rac2 gene is linked to various defects
in white blood cells [48-50]. Most of these inadequacies are probably due to the Rac2-specific
activation of NADPH oxidase [51,52], and production of reactive oxygen species (ROS) in
hematopoietic cells [53]. The generation of ROS is essential in both host defense machineries
[47] and blood cell differentiation signaling mechanisms [50]. Those further anomalies in
hematopoietic cell role observed with a merged Rac1 and Rac2 deficiency highlight the
overlaying and unique functions of these related small GTPases in hematopoietic cells [51].
Rac3 is mostly expressed in brain but is upregulated once the fibroblasts are serum-stimulated
[53]. Compared to Rac1, Rac3 is found more in the membrane [54]. Moreover, it has increased
activity in breast cancers [54] and the Rac3 gene is located near a portion of chromosome 17 that
is oftentimes removed in breast cancers, which might cause its expression to be unregulated [55].
Vincent et al. first delineated RhoG as a “late-response gene” stimulated upon serum activation
of fibroblasts, appearing to be a gene regulated once transcribed, which later participates in cell
cycle regulation [56]. Activation of RhoG mutants lead to lamellipodia development, membrane
ruffling, and formation of filopodia to some degree [57]. The signaling mechanism is unclear;
some reports suggest that it controls its cellular influences via the activation of Rac1 and CDC42
[57]. Other reports suggest that the signaling mechanism is independent of Rac1 and CDC42
[58]. Nevertheless, a recent report suggests that Rac1 is activated by RhoG through the
involvement of the DOCK180 RhoGEF [58].
CDC42-related proteins
The CDC42-related proteins all participate in filopodia formation, mostly via their interaction
with Wiscott-Aldrich syndrome protein (WASP) or N-WASP [59,60] except for Wrch-1, which
10

has no interaction with either WASP or N-WASP [61]. Two isoforms of human and mouse
CDC42 are produced via alternative splicing of the same gene [62,63]. Both isoforms have 191
amino acid residues that vary at residue 163 and in their C-terminal last ten amino acids.
The most studied isoform, placental CDC42 (CDC42p), has a ubiquitous expression, while the
other isoform, brain CDC42 (CDC42b), is found only in the brain.
TC10 [64] and TCL are closely related and have roles that bear much similarity to that of
CDC42 [65]. Filopodia generated by TC10 and TCL are more extended than those stimulated by
CDC42 [66,67]. TC10 and TCL bind to most effectors of CDC42; however, some key structural
contrasts exist between them [66,67]. While the C-terminal CAAX motifs of TC10 and TCL
indicate that they can be modified either by farnesylation or geranylgeranylation, the C-terminus
of CDC42 can only be geranylgeranylated. TC10 can also be palmitate-modified, which allows it
to escape RhoGDI-1 recognition [68]. TC10 and TCL activities appear to be controlled by
extracellular stimuli dissimilar from the ones that control CDC42.
No report yet on the regulation of TC10 and TCL by the Dbl family, which has been said to be
the most frequent activators of Rho proteins [69]. It has instead been suggested that TC10
activation occurs thanks to the Rap GEF C3G once adipocytes have been stimulated by insulin
[70]. Activated TC10 then regulates GLUT-4 migration to the plasma membrane and is essential
for the differentiation of adipocytes [71]. Furthermore, the expression of TC10 and TCL are
upregulated during the nerve regeneration process [72] and neurite cell differentiation [73]; and
activation of TC10 and TCL promotes neurite extension. Two distinct isoforms of TCL have
been found. One is characterized by the presence of an elongation of ten amino acid residues at
the N-terminus [70].
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The rat protein Chp (its human version is called Wrch-2) has been identified as a Pak2serine/threonine-kinase-interacting protein in a yeast two-hybrid screen [74]. Similar to CDC42
activation, activation of Chp leads to its interaction with Pak and N-WASP and induces filopodia
formation [74].
Chp varies from other Rho proteins by its lack of a conventional C-terminal CAAX prenylation
sequence. However, the C-terminus is necessary for its biological functions [74].
Wnt-1 signaling pathway upregulates the gene that codes for Wrch-1 [75]. Wnt-1 binds to the
“Frizzled cell-surface” receptor which caused the APC tumor suppressor to be deactivated and
the transcription activity of β-catenin and transformation to be activated. Wrch-1 expression in
mammary epithelial cells imitates the influences of Wnt-1 transformation on cell morphology
[75] highlighting the importance of Wrch-1 signaling element in Wnt-dependent oncogenesis. To
date, no known RhoGEFs, or GAPs, or GDIs have been reported as regulators of Chp and Wrch1 proteins.
Nonetheless, the capacity of a dominant-negative S45N type of Chp to stop tumor necrosis factor
α (TNF-α)-controlled signaling activity suggests that Chp GEFs may exist. Extra N-terminal and
C-terminal sequences that flank the GTPase domains are found in both Chp and Wrch-1. Prolinerich sequences that may function as Src-homology 3 (SH3) domain recognition sequences are
found in their N-terminal sequences. This indicates that proteins containing a SH3 domain could
identify and mediate their roles. Likewise, the extra C-terminal sequences of these proteins may
help recognize their roles and mediations from those related to CDC42.
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The Rnd subfamily
The three Rnd-family proteins have a 45-49% sequence identity with RhoA. However, they
display biochemical and functional characteristics that are different from those of RhoA
members. They are GTPase activity deficient, they are unstable in both the GDP- and GTPbound states [76], and RhoE/Rnd3 (known as Rho8) is essentially GTP-bound in vivo [77].
They also have a substitution that causes a decrease in the affinity for nucleotides. They are posttranslationally farnesylated instead of geranylgeranylated [78]. They inhibit the stimulation of
contractility, actin formation, and the focal adhesions generated by RhoA GTPase, which
represents a key functional characteristic of RNd1 and RhoE/Rnd3 [79]. This was brought about
by interacting and activating p190RhoGAP and for RhoE/Rnd3 at least, interacting and
deactivating the RhoA effector ROCK1 [80]. Socius is another Rnd effector that could take part
in this activity; however, it is unclear how this assists in the cycling activity of these proteins.
During the fetal development, Rnd1 is ubiquitously expressed; in embryos of Xenopus, its level
of expression is very high in tissues where extensive morphogenetic modifications occur [79].
Nonetheless, in adults, Rnd1 is mostly expressed in the brain and the liver.
The most expression of RNd2 is seen in the testis, the brain, and liver [80]. Very little is known
about its roles, but it has been reported to interacts with proteins such as Vps4-A, a protein that
participates in endosome sorting [79], rapostlin, a protein that is involved in neurite branching
[81], and MgcRacGAP, a RhoGAP that takes part in cytokinesis [82].
RhoE/Rnd3 has been identified as a protein that binds to p190RhoGAP which leads to the
inhibition of RhoA through the mediation of Rnd. The mRNA of RhoE/Rnd3 is ubiquitously
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present, however, the protein expression is very sparse [83]. The transformation of Madin-Darby
canine kidney (MDCK) cells by Raf leads to the upregulation of RhoE/Rnd3 which regulates the
stress fiber removal and multilayer development associated with this transformation.
Likewise, Ras transformation, in human epithelial cells, leads to an upregulation of RhoE/Rnd3
protein expression levels.
The stimulation of Platelet-derived growth factor (PDGF) by fibroblasts promotes RhoE/Rnd3
protein production which is linked to the loss of stress fibers and cell body rounding [84].
RhoD and Rif
RhoD and Rif share up to 48% of sequence similarity and have an extra N-terminal sequence;
however, studies suggest that they might functionally diverge in their impacts on actin
organization [85,86]. These two proteins have been however suggested to have similar roles in
the management of actin organization [87].
RhoD has been reported to have implication in the regulation of two different cell activities
associated to actin. First, it mediates the transport of early endosomes which is actin dependent
[119] via its interaction with the diaphanous-related formin protein hDia2C, which leads to the
activation of Src [88,89]. Second, it stimulates the dismantlement of actin stress fibers and
destruction of focal adhesions and prevents cell motility [87]. It is unknown whether there is
correlation between the two processes. Rif has a very wide expression and contributes to
filopodia development despite its remote relation to CDC42 (43% identity).
Moreover, based on its effector domain sequence, Rif would not be expected to interact with
CDC42 effectors that are involved in the reorganization of actin like N-WASP and WASP.
14

RhoH/TT
RhoH/TTF was initially discovered as a chimeric transcript from a chromosome 3:4 translocation
[90]. It was subsequently named RhoH due to its expression in hematopoietic cells specifically.
The RhoH/TTF gene is mutated or mixed with other genes in diseases like non-Hodgkin's
lymphoma and multiple myeloma [90]. RhoH/TTF contains a Rho insert sequence, but shorter
than that of other Rho GTPases. RhoH/TTF, like Rnd proteins, is deficient in the conserved
residues that correlated with G12 and Q61 that are also found in other Rho GTPases and as a
result is likely to be GTPase lacking, and consequently not controlled by GDP/GTP cycling [90].
The RhoBTB subfamily
RhoBTB subfamily of proteins have been discovered in a database search for Rho-linked
GTPases in Dictyostelium [91]. These unusual Rho GTPases have different structures from the
other Rho-family members and have major extra sequences downstream to the Rho GTPase
domain. The extra C-terminal sequences have a tandem repeat of BTB domains and is deficient
in the C-terminal CAAX prenylation signals. The BTB domain was originally discovered in
the Drosophila transcriptional repressors Broad complex, Tramtrack and Bric-a-brac, and exists
in as many as 200 human proteins [92].
In mammals, this family of GTPases includes three members: RhoBTB-1, RhoBTB-2, and
RhoBTB-3. Both RhoBTB-1 and RhoBTB-2 contain the Rho insert sequence that differs from
the Rho GTPases and other Ras superfamily proteins.
The GTPase domain of RhoBTB-3, nonetheless, is somewhat conserved and atypical of Rho
domain. Therefore, it has been suggested that RhoBTB-3 should not belong to the Rho-family.
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RhoBTB2 was discovered as a deleted gene (DBC2) independently. Whether or not it is mutated,
it is expressed in many breast cancer cell lines and tissue samples [93].
Expression of the wild-type RhoBTB2 prevents formation of T47D human breast cancer cells
[93]; however, this is not the case for the mutated versions found in breast cancers.
The Miro subfamily
The Miro subfamily of GTPases consists of two proteins: Miro-1 and Miro-2 [94]. These two
proteins contain presumably two GTPase domains and two EF-hand motifs. The N-terminal
GTPase domain shares high sequence similarity with that of other Rho GTPases. These two
proteins Miro-1 and Miro-2 have been called atypical Rho proteins since they were discovered
through a database search for proteins having the Rho domain [94].
Nonetheless, based on the divergence of their overall sequence from the other Rho GTPases,
added to a deficiency in the Rho-specific insert sequences, these GTPases should not be part of
Rho family [94,95].
Rho GTPases activities have been thought initially to be controlled by the shuttling between an
inactive, GDP-bound version, and an active, GTP-bound version of the Rho GTPases.
Nonetheless, it has been recently found that their activities are controlled by other ways. These
other types of regulation appear to be essential for the less investigated Rho GTPases.
Regulation by nucleotide binding
The GDP/GTP cycle of Rho proteins is regulated majorly by the GEFs, the GAPs, and the GDIs
[96]. The control mechanism of these three families of regulatory proteins, with some
exceptions, has yet to be fully elucidated. The RhoGEF family is a very large family which
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encompasses as many as 60 members which are part to the Dbl family of proteins [96] and about
ten members which are part of a more recently discovered Dock family [97].
The RhoGAP family, a vast group, counts as many as 80 different members encoded in the
human genome; and the way they are regulated are even less clear than those of the RhoGEFs.
These proteins diverge a great deal in sequence and domain structure but show more sequence
similarity in their RhoGEF and RhoGAP domain [98].
Regulation by lipid modification
Rho GTPase capacity to accomplish its functions depends very much on its anchorage to the
membranes and their subcellular localizations.
These activities are controlled by C-terminal lipid group and sequences, and by binding to
RhoGDIs as well. The level of the cellular dissemination of Rho GTPases indicates their
importance in that location.
Contrary to RhoGEFs and RhoGAPs, the number of known RhoGDIs is very low. Three welldefined RhoGDIs have been identified: RhoGDI-1, RhoGDI-2, and RhoGDI-3; some other
proteins have also been suggested to possess GDI activity towards Rho proteins [99,100]. The
three most studied GDIs appear to differ in their specificity to bind Rho proteins. While
RhoGDI-1 interacts with RhoA, Rac1 and CDC42 with high affinity, RhoGDI-3 binds with high
affinity as well to RhoB and RhoG; they however seem to bind to RhoA and CDC42 with a
lower affinity, but they do not bind to Rac1 and Rac2 [101]. RhoGDI-2 targets are yet to be
found, but it does not readily bind to RhoA, Rac1 or CDC42 [102]. The concentration of
RhoGDI-1 in the cell was compared to that of the target GTPases [103].
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Interestingly, based on the stoichiometry of RhoGDI-1:GTPases, it was suggested that most Rho
protein in the cell are bound to GDIs which leads to their inactivation, which suggest that
binding of Rho to Rho-GDI represents a very powerful way to regulate RhoGTPases. Several
proteins have been found to bind to RhoGDIs and possibly control their binding interaction with
Rho proteins [104,105].
Most Rho GTPases have a terminal CAAX tetrapeptide sequences that are isoprenylated. Some
Rho members have a C15 F isoprenoid, and some others have a more hydrophobic C20
geranylgeranyl isoprenoid tail [106,107]. The geranylgeranyl modification facilitates tighter
association to the membrane; however, the sort of isoprenoid tail does not appear to provide
functional uniqueness, except for RhoB [108-111].
The subcellular location of Rho GTPases is not merely determined by the addition of terminal
lipid group. For instance, Ras proteins require a second C-terminal signal to be wholly
functional. Some protein members are further modified by a palmitate at C-terminal cysteine
residues right after the CAAX motif. Some members have sequences rich in lysine/arginine
residues and some others have both sequence components. The addition of a palmitoyl group can
also impact RhoGDI recognition [110]. For instance, RhoB palmitoylation disturbs RhoGDI-1
identification and impacts subcellular localization as a result [110]. The conventional CAAX
motifs are still absent in members like Chp, RhoBTB, and Miro, shedding doubt on whether their
C-terminal sequences have any relevance in subcellular localization [111].
This variety in the C-terminal sequences of these proteins helps a great deal in diversifying their
roles [112]. RhoGDIs have key roles in the regulation of Rho subcellular localization.
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For example, RhoG is located in the Golgi complex by RhoGDI-3 [113]. RhoA and RhoB are
found at very different locations in the cell [114], probably due to their difference in GDI
binding.
Protein kinase A can control the binding of RhoA to GDI by phosphorylating a C-terminal serine
in RhoA which subsequently leads to the binding of RhoA to GDI [116]; similar binding patterns
have been observed for other RhoA members. Downregulation of RhoGDI-2 is observed in
many tumors; RhoGDI-2-tranfected metastatic cell lines show inhibition in cell metastasis [117].
Regulation by gene expression
A great number of Rho GTPases appear to be tightly controlled by their expression level in
addition to them being regulated by GEFs, GAPs, and GDIs. The level of mRNA and proteins
belonging to the Rho GTPases family such as RhoA, Rac1 and CDC42 are somewhat stable in
most tissues, the expression level of most other Rho GTPases is not.
Several Rho proteins are only expressed in some tissues which is indicative of their specific roles
in these cells. Moreover, among the less studied Rho GTPases, some appear to only be regulated
transcriptionally which suggests that their gene expression is dictated by necessity.
CDC42: functions and structure
The CDC42 gene codes for a 21.3 KDa, 191 amino acids small GTPase [105,106]. Through
alternative splicing, a single CDC42 gene results in two isoforms: isoforme 1 (known as
placental isoform, CDC42p) [107] and isoform 2 (also called brain isoform, CDC42b) [108].
CDC42 is a member of the Rho family and is crucial to many cellular processes including
establishment of cell polarity and morphogenesis [105].
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It was originally identified as an arbitrator of cell division in S. cerevisiae (yeast) [105,106]. In
humans, CDC42 modulates signaling pathways that oversee four main cell processes which are:
cell polarity (which depends on the aysmetrical), transport and endocytosis, actin polymerization,
and RNA processing [20].
It plays key roles in the development of bone formation, cardiovascular, immune, and nervous
systems. Moreover, CDC42 is necessary for the development of the pancreas, blood cells, eye,
and skin [109]. Structurally, CDC42 is a dimer with two homologous chains A and B (figure 4)
[20]. Its domains include a P-loop domain which lodges the nucleoside triphosphate hydrolase
and a small GTP binding domain [20]. A comparison of RhoA-GDP and RhoA-GTP crystal
structures unveils that the conformational contrasts between GTP and GDP-bound configurations
are limited predominantly to the switch I and switch II regions [21].

Fig.4. Structure of CDC42. CDC42 contains two homologous chains: A and B and two
important regions: Switch I and II.
ACK Family Kinases
ACK1 (also called TnK2) is a 120 kDa protein [107] with an N-terminal end that contains a
sterile alpha motif (SAM) domain, a kinase domain, an SH3 domain, and a CDC42/Racinteractive domain (CRIB) [108,109] (figure 5). The C-terminal end of ACK1 contains
important regions such as multiple proline-rich sequences, a clathrin-binding motif [54], a
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ubiquitin binding domain [26], and a region that has a high homology with Mig6 [55]. The
ACK family kinases are the only NRTKs that have a SH3 domain located C-terminally to the
kinase domain. They are as well the only tyrosine kinases that contain a CRIB domain.
ACK1 is the first member of the ACK family. It was cloned from a human hippocampal
expression library via its capacity to bind active CDC42 specifically and not Rac1 or RhoA
[54]. The ACK1 encoding gene is found on chromosome 3q29 in humans which has been
shown to be associated with prostate cancer development and is used as metastatic deterioration
predictor in breast cancer [55].

Fig.5. ACK1 domains arrangement. The ACK family kinases are the only NRTKs that
have a SH3 domain located C-terminally to the kinase domain. They are as well the only
tyrosine kinases that contain a CRIB domain.
In its downregulated conformation, ACK1 is autoinhibited by an intramolecular interaction
between the Mig6 homology region (MRH) and the kinase domain [121]. Phosphorylation and
activation of ACK1 can be promoted by several stimulatory signals such as phosphorylation of
the MHR by receptors like EGFR, the attachment of the poly-proline containing regions to the
SH3 domain, and the binding of GTP-CDC42 to the CRIB domain [123,124]. Upon activation,
ACK1 phosphorylates and activates guanine nucleotide exchange factor Dbl, which in turn
regulates CDC42 by promoting GDP/GTP exchange [125]. Activated ACK1 also phosphorylates
downstream effectors such as p130Cas or WASP to regulate cell adhesion and migration
[126,127].
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Moreover, in its active conformation, ACK1 promotes tumor formation by the phosphorylation
of Wwox (a tumor suppressor), Akt, Androgen receptor (a transcriptional activator) [128].
Rho GTPases in cancer
Rho proteins have been reported to participate in the development of pathological states
including cell migration, invasion, and cell metastasis, inflammation, as well as wound repair in
addition to their physiological roles. It has been reported that Rho GTPases assist in most steps
leading to tumor initiation and progression which include the ability to acquire unrestricted
proliferation ability, survival and evasion from apoptotic mechanisms, invasion into tissues and
the establishment of metastasis.
Primary tumors, by and large, develop due to many mutations and epigenetic modifications
which affect essential genes that eventually impact cell proliferation and survival.
In 15% of all human tumors exist mutations that activate K-Ras, N-Ras, and H-Ras. In contrast
to the Ras family of proteins, Rho family of proteins undergo very little mutation in tumors while
their level of expression and activity is often modified. For instance, various Rho GTPases are
found upregulated in certain human tumors which include RhoA, RhoC, Rac1, Rac2, Rac3,
CDC42, Wrch2/RhoV and RhoF [129,130].
Unrestrained cell proliferation associated with enhanced survival signaling activities allowing
tumor cells to avoid apoptosis lead to tumorigenesis. Certain Rho GTPases trigger cell cycle
progression and mediate gene transcription which could partly elucidate their propensity to
oncogenicity [131]. The stimulation of tumor vascularization is paramount for tumors to develop
and exceed certain size and malignant cells produce factors that facilitate the formation of new
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blood vessels from pre-existing blood vessels in the vicinity. It is thought that some Rho
GTPases can mediate pro-angiogenic factors release to enhance the formation of new blood
vessels [132].
Epithelial cancer invasion begins when the epithelium has become defective and malignant cells
have destroyed the membrane and penetrated the underlying stroma. This usually means the
epithelial cell–cell contacts have become loose and addition of a more moving phenotype in an
activity often called “epithelial to mesenchymal transition” (EMT). Invading epithelial cancer
cells often have decreased expression of E-cadhenin which is the cell-cell adhesion protein and
begin the expression of markers of mesenchymal nature like vimentin and N-cadherin [133].
Non-epithelial cancers migrate into solid tissues as well [134].
Invasion of cancer cells into tissues can be done either individually or collectively. It has been
reported that single cells use two ways to migrate: mesenchymal and amoeboid migration. Cells
undergoing mesenchymal migration possess an extended morphology and expand long
protuberance at the front. Integrin-based adhesion and a solid traction are what drives the
migratory movement in addition to the degradation of extracellular matrix (ECM) by
transmembrane proteases [134]. On the contrary, amoeboid migration does not depend on the
action of extracellular proteases and is assisted by cortical actomyosin-based contraction. When
cells invade collectively, they move together through the extracellular matrix and keep cell–cell
adhesions. The cell located at the front of the group produces the migratory traction needed for
movement and the other cells are pulled passively. The ECM degradation by matrix
metalloproteases (MMPs) is paramount for this sort of group migration [135]. To migrate into
remote tissues, tumor cells have to penetrate the vascular or lymphatic system for proliferation in
the new tissue.
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The capacity of Rho GTPases to control the dynamics of cytoskeleton, cell adhesion and cell
migration [136] highlights their key function in cancer cell invasion and metastasis.
The Rho family consists of subfamilies including RhoA, RhoB and RhoC proteins which are
very conserved. While RhoB expression and activity are frequently diminished in human tumors,
that of RhoA and RhoC are often enhanced in human tumors [137].
RhoA is involved in almost all levels of cancer progression. RhoA may play an important
function during tumor proliferation and survival [137]. In normal epithelial cells, RhoA
participates in the organization of epithelial polarity and junction assembly and function [138].
However, it also has impacts on the destruction of the epithelial during the progression of tumor.
Rho action can be prohibited by adherins which can cause the phenotype to be more
mobile [139].
Distinct GEFs and GAPs have impact on the actions of Rho proteins in different situations either
assisting in the organization of the epithelia and polarity or in epithelial EMT [140].
RhoA is crucial for migration done according to the amoeboid and mesenchymal way. It is
suggested that RhoA-ROCK signaling stimulates cortical contractility based on actomyosin
resulting in amoeboid migration by blistering and in tail withdrawing in mesenchymal migration
as well [138]. It was shown in a 3D in vitro invasion model done with co-cultures of SSC12
carcinoma cells, which have not been transformed in the mesenchymal mode that keep certain
epithelial markers, that stromal fibroblasts have displayed a fibroblast directing cell in this
version of group cell invasion [141]. This fibroblast cell produces the necessary pulling power
and reshapes the matrix via MMPs.
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It was found that many Rho GTPases were needed in the commanding fibroblast and the other
tumor cells where a RhoA protein controls the myosin light chain (MLC) in the leading cell and
mostly CDC42 and MRCK role in the following cells.
It has been further demonstrated that Rho GTPases can control MMPs synthesis, influencing
matrix reshaping and tumor cell invasion. Moreover, Rho can stimulate MMPs expression or
secretion [142].
RhoC has not been reported to have any transforming action contrary to RhoA. The contribution
of RhoC in cancer seems to be limited majorly to metastasis [143]. Research conducted on
melanoma metastasis found that RhoC gene expression was upregulated [144] and has as a result
been suggested being a marker for low prognosis in different cancers[145].
Enhanced RhoC expression has been proposed to be the possible reason for the increase in
invasion and metastasis stimulated by microRNA-10b overexpression in breast cancer [146].
Research on RhoC knock-out mice indicated that RhoC is not required for tumor initiation and
embryogenesis yet is indispensable in metastasis.
There is an increase in RhoC expression during EMT in a colon cancer model and assists in
migration induced by EMT, while RhoA expression levels decrease. Studies involving knocking
down RhoC gene by RNAi reveal that RhoC is crucial for cell invasion in vitro. It is yet to clarify
the mechanism by which RhoC stimulates invasion and metastasis or the reason for varying
impacts from RhoA.
Studies largely done on chemical inhibitors show that RhoA and RhoC and their following target
ROCK are necessary for cancer cell leaking and secretion [147]. Surprisingly, RhoC can
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stimulate angiogenic factors synthesis in breast cancer which could assist in facilitating invasion
into blood vessels and causing metastasis. Further work is necessary to clarify the probable
assistance of Rho GTPases in the leaking of cancer cells.
RhoB expression often plummets in human tumors and its expression level usually goes down as
a tumor becomes more aggressive, which is not the case for RhoA and RhoC [148]. RhoB has
been suggested to function as a tumor suppressor as it becomes active as a result of the
production of several stress stimuli including DNA damage or hypoxia. It has also been reported
that RhoB prevents tumor development and metastasis and play keys roles in cell
proapoptotic activity. RhoB knock-out mice grow well but develop increased carcinogeninduced skin tumor, which is in concurrence with a function of tumor suppressor carried out by
RhoB [149].
RhoB also decreases cell invasion: for instance, it has been argued that RhoB works downstream
of PKCτ to control cancer cell invasion in vitro [150] and reports also showed that it decreased
invasion and metastasis induced by Ras proteins [151].
The suppression mechanism by which RhoB works to suppress tumor development and invasion
is yet to be elucidated; its function in endosomal trafficking could play a role in that. RhoB
controls proteins delivery which include growth factor receptors and the tyrosine kinase Src to
cell compartments that are very specific [152]; this may have some effect on cell proliferation
and invasion.
CDC42 and its very closely related Rho proteins such as RhoQ/TC10 and RhoJ/TCL constitute a
unique Rho GTPases subfamily. There is an increase in the CDC42 expression level in some
breast cancers [153], yet it is reported that the deficiency in CDC42 promotes liver cancer
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formation in a liver-specific knock-out study [154]. This suggests that the participation of
CDC42 in cancer development might be tissue specific. This could explain the various functions
of CDC42 in adjusting cell polarity as well as cell cycle continuation.
CDC42 and RhoQ/TC10 promote cell transformation and assist in cell transformation caused by
Ras [155]; CDC42 contribution to cell transformation is proposed to be a result of its influence
on receptor trafficking and degradation [156]. RhoQ/TC10 is also involved in receptor
trafficking, especially of the glucose transporter [157]. However, it is not known whether this
helps in its contribution to cell transformation. Another way CDC42 could influence cell cycle
continuation is by controlling chromosome separation during mitosis [158]. Among all Rho
GTPases, only CDC42 gene knockdown was determined to trigger “chromosome misalignment”
during mitosis which caused cells to be multinucleated.
CDC42 participates in the organization of epithelial polarity. It also contributes to migratory
polarity through binding to the Par3/Par6/aPKC polarity complex, which subsequently controls
Rac via Tiam1 [159]. It is predicted that CDC42 prevents invasion by enhancing epithelial
polarity, but also causes migration inversely.
Therapeutic strategies to target Rho-related cancers
Targeting the signaling pathways regulated by Rho proteins has gained much attention recently
in the cancer drug discovery field, with strategies aiming at CDC42 which can also be potentially
applied in neurodegenerative and infectious diseases [160-163]. Inhibition of CDC42-mediated
pathways can be done using several strategies which include inhibition of the post translational
lipid modification, inhibition of CDC42 regulatory proteins and CDC42 downstream effector
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interactions, direct inhibition of effector kinases, and covalent irreversible inhibition of
nucleotide exchanges assisted by GEF.
Tackling CDC42 nucleotide binding
Since the activity of Rho GTPases is mediated by the nucleotide they are bound to, a simple
strategy would be to prevent GTP from binding to Rho GTPases. Many reports on the strategy
aiming at inhibiting GTP from binding to Rho GTPases have detailed the challenges for the
design and generation of small molecules being able to target the nucleotide binding sites of
GTPases and successfully compete with the picomolar binding affinity of the nucleotide [164].
Despite all the adversity encountered, the use of this approach has led to the discovery of small
molecule inhibitors like ML141 [163] (figure 6) and R-Ketorolac (figure 7) [165].

Figure 6. Structure of ML141
ML141 was discovered in an in-silico screening against key members of the Ras superfamily due
to its capacity to diminish GTP binding to CDC42. ML141 was proposed to interact with an
allosteric site of CDC42 to cause GTP dissociation. Nevertheless, ML141 does not have any
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inhibitory effect on cell migration [165]. Likewise, R-Ketorolac works as allosteric inhibitor of
GTP to CDC42 and Rac1 which is closely related to CDC42 [166].

Figure 7. Structure of R-Ketorolac
Studies show that ovarian epithelial cancer cell lines that were treated with the small molecule
R-Ketorolac displayed decreased migratory and invasive behaviors [167].
Tackling CDC42–GEF interactions
Targeting CDC42 can also be done through directly targeting specific CDC42–GEF complexes
interfaces. This strategy has led to discovery of several small molecule inhibitors [168,169]. In
this strategy, the biggest challenge arises from the overlaying interfaces between specific
CDC42–GEF and the indiscriminate binding activity of the GEFs to Rho proteins [170,171],
which leads to small molecule inhibitors lacking in potency and specificity. This has led to many
small molecule inhibitors with pan or dual inhibitory properties towards Rho proteins like
CDC42 and Rac1. Concerning pan Rho family small moelcule inhibitors, it can be suggested that
designing drugs with a more promiscuous binding pattern can be more advantageous to
overcome resistance to a treatment against a single Rho GTPase protein target, since many of the
cell functions of Rho family GTPases depend on a defined equilibrium between several Rho
family members [172]. However, investigating and evaluating the singular biological effects
resulting from inhibition of CDC42 requires specificity and selectivity within the Rho proteins.
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Tackling CDC42–GEF interfaces
CDC42-Intersectin (ITSN1) is the complex having been targeted the most [173]. ITSN1 is a GEF
specific to CDC42 [174] and is also the RhoGEF that has undergone the most mutations in some
cancers [175]. ZCL278 (figure 8) was identified as a small molecule inhibitor by a high
throughput virtual screening where small molecules were designed to dock into the ITSN1
binding pocket of CDC42.

Fig. 8 Molecular structure of ZCL278
It was predicted that ZCL278 would H-bond with Thr35, Asn39 and Asp57 of CDC42 as well as
hydrophobically interact with Val36 and Phe56. It is with low micromolar affinity that ZCL278
binds to CDC42 and was found to inhibit various cell activities mediated by CDC42 [175].
Despite its inhibitory prowess, ZCL278 was soon proved to be a partial agonist of CDC42 in
some situations, and focus was shifted from ZCL278 to ZCL367 [176]. ZCL367 has enhanced
potency and better selectivity in another screen assay conducted on A549 and PC3 cell migration
[176]. It was also found that ZCL367 possesses select potency towards CDC42 (IC50 = 0.098
µM) over RhoA (IC50 = 29.7 µM) and Rac1 even if it is relatively much less potent (IC50 = 0.19
µM). Prevention of migration and proliferation has been demonstrated in studies involved lung
and prostate cancers driven by EGFR and Ras [176]. Moreover, ZCL367 was shown in a lung
cancer xenograft mouse model to reduce tumor development upon ZCL367 therapy and filopodia
formation mediated by CDC42 was reduced in cell lines [176].
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CASIN (figure 9) is another small molecule that interacts with CDC42-GDP with a ∼300 nM
affinity and prevents the dissociation of GDP catalyzed by the CDC42-Intersectin complex
[177,178]. Docking studies reveal that CASIN interacts with inactive CDC42 at a site adjacent to
the switch I where a Met45 residue would create a critical binding interaction: mutation of
Met45 (M45E) disrupted CASIN ability to bind CDC42.

Fig. 9 Molecular structure of CASIN
It has been demonstrated that CASIN prevents the mobilization of F-actin and cell migration
[179]. Lately, it has been found that CASIN prolonged murine lifespan by a period of four days,
revealing an interesting optional route to inhibit CDC42 [180].
Targeting the nearest relative of CDC42, Rac1, has been very advantageous in the search for
CDC42 inhibitors. NSC23766 (figure 10) is a small molecule produced initially to prohibit the
interaction between Rac1-Trio and Rac1-Tiam1[181].

Fig. 10 Molecular structure of NCS23766
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NSC23766 was discovered through in silico screening as a small molecule that bound at the
GEF-recognition pocket of Rac1 which centers on Trp56 residue. Ehop-016 was another small
molecule formed from NSC23766 with both molecules possessing a central pyrimidine ring with
six members [182]. It was found to inhibit Rac1 with a 1.1 µM affinity; it was also found that
Ehop-016 inhibits the activity of CDC42 at a 10µM concentration [183]. MBQ-167 was also
discovered by the same group in virtual screening to discover a small molecule that is able to
bind deeper into the NSC23766 binding pocket found on Rac1, through the exploitation of a Hbond formation with Asn39 residue. Asn39 is found in switch I of Rac1 and CDC42, which
makes MBQ-167 a dual CDC42/Rac1 inhibitor with IC50 of 103 nM for Rac1 and an IC50 of 78
nM for CDC42. Characterization studies of the small molecule MBQ-167 led to a preclinical
mouse model where it prevented the development of HER-2 type tumor and invasion in
immunocompromised mice [184].
NSC23766 has been used to construct small molecules being able to target the CDC42-Dbs
[182]. AZA1 (figure 11) is a small molecule that was reported to have the potential to inhibit
Rac1–GEF complex formation [185].

Fig. 11 Molecular structure of AZA1
It was shown that AZA1 was a dual inhibitor for Rac1 and CDC42, with the capacity to suppress
both Rho GTPases activities [186].
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The potency of AZA1 is relatively low, which suggests the existence of many bonds that are
very flexible inside the small molecule [186]. AZA197, a more restrained small molecule, has
recently been synthesized, which is found in the classic ‘flat’ small molecule chemical pocket
[187].
Targeting the interaction of CDC42–Dbs led to satisfactory specificity, without any prohibition
of Rac1 or RhoA and with a decreased nucleotide exchange for CDC42. AZA197 was shown to
prevent proliferation, cell migration and invasion in both HT-29 and SW620, two colorectal
cancer cell lines. AZA197 was further shown to reduce tumor development in a murine
xenograft model using SW620 cells [187].
Tackling cysteine through irreversible inhibition
A completely different method of prohibiting CDC42–GEF interaction is the use of a cysteine
residue next to but not within the interface of the two binding proteins (CDC42-GEF) that causes
inhibition of nucleotide exchange catalyzed by GEF. A group of covalent, irreversible small
molecule inhibitors have been made lately to target RhoA Cys107 residue [188]. DC-Rhoin04,
the tightest binder, prevented RhoA nucleotide exchange with a IC50 of ∼3 µM [188]. All these
molecules possess electron-deficient alkenes that can react with the nucleophilic cysteine. The
cysteine of interest exists merely in Rho proteins and as a result brings about selectivity over the
other members of Ras superfamily. It was revealed that the crystal structure of the DC-Rhoin04RhoA complex contains a binding pocket, called the CLocK pocket, which expands from
Cys107 residue and is stimulated by DC-Rhoin04 binding interaction. CDC42 Cys105 is thought
to be DC-Rhoin04 site of action, permitting it to prevent the CDC42-intersectin binding.
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It was shown that DC-Rhoin04 suppressed cell migration and invasion in the breast cancer cell
line MDA-MB-231.
Small molecules inhibiting cysteine covalently possess the capacity to promiscuously bind to
other Rho proteins with other cysteines located on off-target protein surfaces and display toxicity
if the small molecule inhibitor is very sensitive or specificity deficient [189].
The off-target capacity to cross-react with the compound DC-Rhoin was probed and it was
shown to have no inhibitory activity against Ras proteins, which lacks the Cys105/107
counterpart [188]. It is yet to be probed the timescale of DC-Rhoin target inhibition since this is
very important for their success as prolonged inhibition can lead to cell toxicities [190].
Producing an irreversible inhibitor strategically targeting a cysteine has seen the most success in
the targeting of K-Ras G12C mutations [191], which led the small molecules MRTX849 (figure
12) and AMG-512 to clinical trials [192]. These small molecules target an oncogenic GDPbound, inactive K-Ras with a cysteine mutation [193]; however, wild type RhoA/CDC42
Cys105/107 can also be targeted by the DC-Rhoin small molecules. DC-Rhoin interacts with the
inactive form and may as well bind the active form if the cysteine residue is exposed to the
solvent. DC- molecule binds at the CLocK binding groove that is next to, yet distinct from the
binding site that is targeted in K-RasG12C.

Fig. 12 Molecular structure of MRTX849
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Tackling CDC42-effector interfaces
Another approach to target Rho proteins is to develop peptide or small molecules that can target
CDC42-effector interfaces [194]. This approach takes advantage of the selectivity of the effector
proteins for their target.
CDC42 binding peptides from a CIS display screening were selected and were used for the
design of second-generation peptides which display low nanomolar binding affinity for CDC42.
It was shown by mapping using NMR chemical shift that the second-generation peptides bind far
from the switch regions yet displaying binding clash for a group of CDC42 effectors like ACK,
WASP and PAK1. It was shown that binding shows a small difference between inactive CDC42
and active CDC42, which indicates that the peptide inhibitors promiscuously target both CDC42GDP and CDC42-GTP [195].
Recently, peptides have been recognized as a fast-growing therapeutic method just in between
small molecules and antibodies. Advancement in the integration of “non-canonical amino acids”
to widen the advantageous virtues of peptides according to prior characterization work on
protein–protein interfaces [196], “molecular grafting” [197] and new cellular means for delivery
which include cell-penetrating peptides [198] and nanoparticles [199], which indicate some of
the recent progress solving stability and delivery problems.
Moreover, new therapeutic strategies like nanobodies, “target-binding fragments of monoclonal
antibodies”, and PROTACs show the tendency to prevent or decrease cytosolic protein levels
through degradation by proteosomes. While these strategies have not seen any application in the
case of CDC42, nanobodies have been developed to selectively bind the GTP-bound form of
RhoB, and consequently can be considered a new strategy to inhibit Rho proteins [200].
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Tackling directly CDC42 effectors
CDC42 downstream effector proteins show many potential targets for drug design. Cancer
mutational data have shown that, CDC42 kinase effector proteins like PAK1, PAK2, PAK4,
MRCKα, MRCKβ and ACK which have been targeted directly, display the biggest level of
modifications among the CDC42 effector protein. Nonetheless, despite their druggable
properties, they are at a disadvantage since they present similar specificity and resistance
problems that are also found when targeting other kinases [201].
Problems in finding selectivity for the protein kinases downstream of CDC42 majorly stem from
the fact that the ATP binding site is structurally very conserved, since the majority of kinases
have a common conserved Asp-Phe-Gly (DFG) motif which is able to exist in two different
conformations [202]. Category I inhibitors impede the kinase in the ‘DFG-in’ active state and
“compete” with ATP, creating key H-bonds with the “kinase hinge region”. Category II
inhibitors interact and maintain a kinase in its inactive ‘DFG-out’ state, filling both the ATPbinding pocket and a hydrophobic allosteric site developed in the inactive state. Allosteric
inhibitors of type III and IV show promising options to reach kinase specificity.
Category III inhibitors interact with and bind at a site near the ATP groove with no contact with
the “hinge region” and in a hydrophobic groove developed in the DFG-out state. Category IV
inhibitors bind at a unique allosteric pocket, remotely from the catalysis site. Categories I, II and
III inhibitors have been illustrated for effector kinases of CDC42.
The PAK family of proteins have been the object of much research; however, progress in
developing PAK inhibitors has been obstructed by problems related to specificity and toxicity
since they are ubiquitously expressed.
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A loose ATP binding rift has been found in the PAK proteins [203], which may partially
illustrate the issues for finding specific type I inhibitors. PF-3758309 binds at PAK4 ATP
binding site, H- bonding with the hinge region and creating an important ionic interaction with
Asp458 of the DFG motif through its dimethylamine group [204]. PF-3758309, nonetheless,
failed phase I clinical trials because it does not provide dose-dependent efficacy since it was
revealed to be a multi-drug transporter P-glycoprotein substrate [205].
KPT-9274, PAK4 Type II allosteric modulator, reached a Phase I clinical trial for its efficacy in
advanced solid malignancies and non-Hodgkin's lymphoma. KPT-9274 is a “dual inhibitor” of
PAK4 and nicotinamide phosphoribosyl transferase (NAMPT), which is a metabolic enzyme that
catalyzes the first step in the pathway that leads to the biosynthesis of NAD+ from nicotinamide
[206-208]. It was found that KPT analogues interacted with PAK4 by chemical proteomics, but
impediment of NAD+ biosynthesis was also documented. It was revealed through a CRISPRinduced drug resistance study that NAMP is the main target for KPT-9274. NAD+ is an
important proliferation metabolite and tumors rely on it to rapidly grow [209]. Dual inhibition of
NAMPT and PAK4 signaling has found therapeutic use in many cancers due to cooperative
actions [210].
KPT-924 hydrophobically interacts with DFG motif Phe193 and NAMPT Tyr. No structure of
KPT-924-PAK4 complex exists, but it is suggested that it binds at the same location on PAK4.
The capacity of KPT-9274 to impede kinase-independent functions of PAK4 as well may also
lead to beneficial drug properties over the type I inhibitor PF-3758309.
There has also been some advancement in targeting other CDC42 kinase effector proteins, for
instance, the small molecule inhibitors of MRCKα and MRCKβ, BDP8900 and BDP9066.
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It was reported that through “structure-guided fragment elaboration”, BDP8900 and BDP9066
were discovered as stronger binders of the MRCK ATP-binding site than the initially discovered
BDP5290 [211]. Hematologic cancers were reported to be the most sensitive to BDP9066 in a
study consisted of screening up to 750 human cancer cell lines across 40 cancer types. It was also
shown that BDP9066 had therapeutic property in skin cancer, for instance, skin papilloma
growth was diminished upon tropical treatment of BDP9066 in a model of murine squamous cell
carcinoma [212]. In summary, developing stronger and selective small molecules should
facilitate the understanding of their potential inhibitory property towards MRCK in cancer [213].
There has not been much progress in the search for ACK inhibitors, and the ones that have been
reported merely target the ATP-binding site [214]. The most studied and understood ACK
inhibitor is AIM-100. Many molecules initially engineered to target other kinases also show
inhibitory activity toward ACK as all those molecules aim at the very conserved ATP binding
site. For instance, NVP-TAE684, a small molecule inhibitor of the oncogenic tyrosine kinase,
NPM-ALK [215] also binds ACK with a 2 nM Kd [216]. However, NVP-TAE684 has not
progressed due to potential toxicity issues.
The pathways of PAK and MRCK converge downstream on LIM kinases. Major challenge has
been encountered when trying to find selective Type I and II inhibitors for LIMK1 and LIMK2,
because of their 71% sequence identity in the kinase domain [217]. Nonetheless, various
compounds have been designed and constructed which possess high binding affinities and
promising pharmacokinetic virtues [218]. Several type I kinase inhibitors and allosteric
compounds have been discovered for LIMK1 and LIMK2. It has been reported that a dual
inhibitor of LIMK2 and ROCK, LX7101, has finished a Phase 1/2a research study in primary
open-angle glaucoma and ocular hypertension, the data are not available yet.
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Sulfonamide compound, the first Type III inhibitor known as LIMK2 ‘compound 22’, binds in a
hydrophobic groove in the inactive DFG [219].
Inhibiting CDC42 anchorage to the membrane
Another strategy to target CDC42 is to prevent their anchorage to the membrane. CDC42
undergoes post translational modification at its C-terminus by a prenyl group; preventing this
modification from occurring has been probed. The transfer of the prenyl group is catalyzed by
type I geranylgeranyl transferase (GGTase I) and several small molecules with potential
inhibitory activity toward this enzyme have been synthesized. Moreover, statins, which show
inhibitory actions against the synthesis of a GGTase I substrate, geranylgeranyl pyrophosphate,
have been probed as well. Nonetheless, the vast number of proteins that are natural substrates for
the geranylgeranyl transferases causes unnecessary inhibition of other protein functions, which
leads to severe side effects. This can illustrate why no GGTase small molecule inhibitors so far
have found approval for clinical purposes [220].
Galanthamine, a natural analog of secramine A, prevents membrane attachment of
geranylgeranylated CDC42 [221]. It was found that the inhibitory influence of Secramine A
depends on RhoGDI-1, which serves as molecular chaperone that transports Rho GTPases from
the cytosol to the targeted membranes.
Involvement of ACK1 and CDC42 in Cancer
ACK1 is involved in numerous stages and various cancers as studies conducted on the survival
of cells transformed by v-Ras revealed that ACK1 was required for the survival of transformed
cells [222].
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A study of about 180 advanced-stage cancers revealed that up to 9% of the lung tumors and 14%
of the ovary tumors displayed an overexpression of the ACK1 gene on chromosome 3 [160].
ACK1 mRNA was found to be overexpressed in 42% of the aggressive lung tumors and 77% of
metastatic hormone refractory prostate tumors [161]. Furthermore, overexpression of ACK1
generated various epithelial-to-mesenchymal transition (EMT) phenotypes in human breast
cancer cell line MDA-MB-231. Mutational studies found that activation of ACK1 by a somatic
point mutation led to EMT phenotypes in renal cancer cells [223].
As many as 41 mutations of CDC42 have been found in various cancers [224]. CDC42(G12V)
was found in a melanoma biopsy as an oncogenic Ras mutation [225], CDC42(F28L) was shown
to promote cell growth and malignant transformation of NIH 3T3 cell lines [226]; fast-cycling
CDC42 mutants can exchange GDP for GTP yet still hydrolyze GTP and thereby promoting
tumorigenesis. Some CDC42 mutants that cannot hydrolyze GTP (slow-cycling mutants) are
kept in the active conformation and oftentimes prevent cell growth [226].
Influence of a Small Molecule on Ras-related proteins
The continuous necessity for small molecule inhibitors (SMIs) to tackle aberrant signaling
processes triggered by Ras proteins in which ACK1 and CDC42 are directly involved makes
them promising therapeutic targets. Based on the classic “GTPase cycle” model of Ras proteins,
CDC42 alternates between an inactive GDP-bound state and an active GTP-bound state. The
binding of GTP to CDC42 and the hydrolysis of GTP γ-phosphate to GDP are strictly modulated
by regulatory proteins such as GEFs, GAPs, and GDIs [2,3]. Upon CDC42 activation, CDC42
arbitrates signaling cascades leading to the activation of more than 20 downstream effector
proteins including protein and lipid kinases, scaffolding proteins, and cytoskeletal interacting
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proteins bringing about modifications in cell processes such as cell polarity, adhesion, migration,
growth, actin cytoskeleton formation, membrane trafficking and transcription. Each step of this
cycle is tightly controlled [3].
Evidence shows that cell transformation occurs as a result of deregulation at either the GDP/GTP
exchange level or at the GTP hydrolysis level of the GTPase cycle [167]. Cell transformation can
also occur due to mutated enzymes involving in the migration and attachment of CDC42 to the
cell membrane. Moreover, it may also stem from a mutated CDC42 that escapes the regulatory
mechanisms, becomes overexpressed, and leads to anomalous activation of downstream effectors
via abnormal signaling cascades. To solve this problem, drug candidates are designed with the 3D structures of the wild type and mutated CDC42 in mind. Strategically, new SMIs can be
designed and constructed that: 1) inhibit impaired specific GEF- or GAP-CDC42 complex
formation, 2) hinder GTP-to-CDC42 binding, 3) impair CDC42-effector protein binding
interactions, 4) restrict CDC42 from localizing to the cell membrane. To this end, SMI have been
designed and constructed with varying level of success.
Among these SMIs, ZCL278, a 4-bromine-2-chlorophenol derivative (figure 8), has been so far
very promising for its disruptive action on the binding of CDC42 with intersectin (ITSN1), a
CDC42-specific GEF. ZCL278 can target CDC42 switch I binding pocket in which it binds to
prevent CDC42- intersectin interaction. This CDC42-ZCL278 complex displays promising
results in cancer treatment and ZCL278 shows itself to be very promising thanks to its high
membrane permeability and low toxicity [175].
ZCL278 has been identified via high throughput in silico screening by Friesland et al. Molecular
features of the CDC42-ZCL278 binding interaction remain lacking.
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Nonetheless, using fluorescence spectrometry and surface plasmon resonance, studies revealed
that there was direct binding between CDC42 and ZCL278 [175]. Furthermore, it was also
shown that ZCL278 could bind to CDC42 via the switch I domain, which is the domain to which
effector proteins bind to elicit intracellular responses [175].
Although ZCL278 was proven to be a promising CDC42 SMI, much remains to be known about
their binding interaction such as the identification of key residues involving in this binding, the
possibility that inactive CDC42 to bind to ZCL278, the identification of structural features of
ZCL278 that promote its binding to CDC42, exploring the possibility of ZCL278 to bind to
CDC42 downstream effector proteins such as ACK. Thus, our goal is to investigate the influence
of ZCL278 on CDC42-ACK binding interaction and to characterize CDC42 wild type and
CDC42F28L in the presence of ZCL278. To achieve that goal, E. Coli were used to express
CDC42, CDC42F28L, and ACK peptide (504-545). Then, biochemical, and biophysical
techniques such circular dichroism spectroscopy, fluorescence spectroscopy, in vitro binding
assay, isothermal titration calorimetry, and GTP/GDP exchange assay were used to investigate
the influence of ZCL278 on CDC42-ACK interaction and characterize the wild type and mutant
CDC42.
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CHAPTER TWO
Characterization of CDC42 and ACK interaction in the presence of the small molecule inhibitor
ZCL2782
Abstract
The Ras superfamily of small GTPases are involved in cell-signaling processes that, if not
regulated, may lead to aberrant cell multiplication, cell death inhibition, and tumor formation.
They operate as molecular switches, which through GTP/GDP exchange cycles, switch on and
off cellular processes. Overexpression of these proteins has been linked to many cancers.
CDC42, a member of the Rho family of the Ras superfamily of small GTPases, is involved in the
regulation of many cellular processes including cell adhesion, mitosis, and cytoskeletal
rearrangement. It binds and activates many effector proteins including CDC42-activated kinase
(ACK). Aberrant activities of CDC42-ACK interactions have been associated with tumor
development and metastasis. It is of utmost importance that small molecule inhibitors be
designed and constructed to inhibit CDC42 interactions with its effector proteins leading to
abnormal signaling activities. A small molecule inhibitor, ZCL278, has been shown to interact
with CDC42 and alter CDC42-stimulated overactivity. In this work, we investigated the
influence of ZCL278 on CDC42-ACK interaction using techniques including fluorescence
spectroscopy, in vitro binding assay, isothermal titration calorimetry, and circular dichroism
spectroscopy. Our data suggest that ZCL278 overall perturbs CDC42/ACK interaction. Our In
vitro binding assay data show that ZCL278 decreased the binding affinity between CDC42, and
ACK. sNBD-CDC42 fluorescence titration experiments data suggest that ZCL278 lowered the
binding affinity of CDC42 for ACK from 0.2 μM. to 1.6 μM.
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Isothermal titration experiments data, consistent with our fluorescence quenching data, show that
the presence of ZCL278 decreased CDC42-ACK binding affinity by interfering with CDC42ACK binding interaction causing the apparent Kd value to increase from 0.6 μM to 4 μM..
Introduction
CDC42 belongs to the Rho family of the Ras superfamily of small GTPases [1]. It is involved in
the modulation of many cellular activities including cell adhesion, mitosis, and cytoskeletal
rearrangements [1]. CDC42 interacts with many effector proteins including ACK1 to carry out
its functions [2]. ACK1 was originally identified as a non-receptor tyrosine kinase (NRTK) [3],
and as such links receptor tyrosine kinases to effector proteins [3]. Inactive ACK1 is found in an
autoinhibited state stabilized by a molecular interaction between its Mig6 homology region
(MHR) and its kinase domain [5]. Through its interactions with effector proteins like AKT, AR
(androgen receptor) and ER (estrogen receptor), ACK1 contributes to the development of many
cancers including prostate and breast cancers and is found continually activated in many other
cancers [6]. ACK can be activated by various ligands including EGF and insulin and can also be
activated by CDC42 with which it interacts via its CRIB (CDC42/Rac Interactive Binding)
region [7]. Abnormal activity and overexpression of CDC42 have been associated to cell
proliferation and malignant transformation [8]. Aberrant activity of the CDC42-ACK signaling
pathway contributes to prostate cancer by phosphorylating and activating AR and degrading
tumor suppressor Wwox [9]. Consequently, attempting to block CDC42-ACK signaling pathway
leading to cancerous and diseased states has been the object of much research for drug candidate
targets. ZCL278 is a small molecule inhibitor reported to impede CDC42 dysregulated actions in
vitro [10]. In our lab, ZCL278 has been used in characterization work involving CDC42 and
CDC42T35A.
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In this research project, we probed the influence of ZCL278 on protein-protein interactions
involving CDC42 and ACK using biochemical and biophysical approaches. Our in vitro binding
assay data suggest that ZCL278 decreased binding between CDC42 and ACK. Extrinsic
fluorescence quenching data suggest that ZCL278 altered the binding affinity of CDC42 for
ACK by an eightfold decrease. Isothermal titration calorimetry data was consistent with our
fluorescence quenching results as they showed that the presence of ZCL278 modified CDC42ACK binding affinity by a tenfold decrease.
Materials and Methods
Protein Expression
6His-CDC42 and GSTACK were expressed in pET-15b and pGEX vectors as 6His-tag and GST
fusion proteins, respectively in the lab. GSTACK plasmid was a gift from Dr D. Owen from
Cambridge University.

Figure 1. Amino acid sequence of ACK (448-489) and CDC42
Recombinant Protein Production
Escherichia coli BL21 cells were used to express recombinant proteins. Seed cultures expressing
6His-CDC42 and GSTACK were diluted in fresh 2TY growth medium (1:10) and grew to
OD600 0.5-0.8, 0.7–0.9 at 37 °C respectively. Upon reaching the desired OD600, they were
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induced with isopropyl-β-d-1-thiogalactopyranoside (IPTG) (0.5 mM) for 4 h (CDC42) and 5 h
(GSTACK). Proteins were purified by affinity chromatography with Histrap HP (6His-CDC42)
(GE Healthcare) and Gstrap 4B columns (Sigma-Aldrich) on the ÄKTA start protein purification
system (GE Healthcare). GSTACK was eluted with 10 mM reduced glutathione (20 mM Tris,
pH 8.0). Upon purification, 6His-CDC42 and GSTACK were dialyzed in 1x PBS pH 8.0 and pH
7.4 respectively. The GST moiety was cleaved with thrombin and removed via heat treatment.
Protein concentrations were measured by using the extinction coefficient of each protein. Purity
of proteins was verified with SDS-PAGE.
Heat Treatment
Previously designed in Dr Kumar and Adams’ lab [11], the heat treatment consists of heating the
thrombin-cleaved products (GST and peptide) until the GST moiety aggregates. Upon heating,
the sample was centrifuged twice, and the supernatant (containing the soluble peptide) was kept
and stored for follow-up experiments. Briefly, upon thrombin cleavage the sample was incubated
at 80-90 °C for 25 minutes. It was then centrifuged twice for 10 minutes at 14K RPM in a
microcentrifuge. The soluble supernatant was then frozen for downstream experiments and the
aggregated pellet was discarded.
Nucleotide Exchange
CDC42 is synthesized in the GDP-bound inactive state. CDC42 must undergo nucleotide
exchange (GDP/GTP exchange) for it to become active. The process involves the exchange of
GDP for GTP in the presence of EDTA and an excessive amount of GTP analog (β, γMethyleneguanosine 5′-triphosphate) enough to competitively displace GDP from nucleotide
biding pocket.
64

Briefly, GDP-CDC42 was mixed with 5 mM EDTA and GTP analog (1:10 ratio) and incubated
on a rocker at 4 °C for 3 hours. GDP, EDTA and the excess unbound GTP were removed with a
PD-10 desalting column upon incubation. The pooled protein was then detected with the
Bradford reagent, combined into one sample to which was added 10 mM MgCl2, lyophilized,
and stored for downstream experiments.
ZCL278 Stock Solution Preparation
ZCL278 (figure 3) was purchased from ApexBio Technology (cat #A8300) and prepared in
100% DMSO. It was then aliquoted (20 mM aliquots) and stored at -20 °C.

Figure 2. Chemical structure of sNBD
Intrinsic GTP Hydrolysis Assay
GTPases constitute a large group of hydrolase enzymes binding to the nucleotide guanosine
triphosphate (GTP) and hydrolyzing it to guanosine diphosphate (GDP).[1] The GTP binding
and hydrolysis occur in the highly conserved P-loop G domain, a protein domain common to
many GTPases. In this experiment, we aimed at studying the impact of ZCL278 on the CDC42
intrinsic GTP hydrolysis in the presence of ACK.
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GTP hydrolysis experiments were conducted according to the kit manufacturer (Promega).
Experiments probing the intrinsic GTPase activity of CDC42 were conducted on CDC42 alone,
CDC42/ACK, CDC42/ZCL278, and CDC42/ZCL278/ACK. All experiments were conducted in
triplicates. In all experiments, an equimolar concentration (5 μM) CDC42 and ACK, and 20 μM
of ZCL278 were used.

Figure 3. Chemical structure of ZCL278
In Vitro Binding Assays
In vitro binding assays are affinity-based assays which consist of binding either two purified
proteins together or two proteins from a crude protein lysate. The protein-protein complex is then
purified via affinity-based purification since one of the proteins bound together carries an affinity
tag. This technique is used to determine the physical interaction between two proteins. However,
in our current work it was used to study the influence the small molecule inhibitor ZCL278 on
the formation of CDC42-ACK complex. Briefly, equimolar concentrations of CDC42 and
GSTACK (200 μM each) were incubated in the absence and presence of 50 μM ZCL278 in 20
mM Tris, 100 mM NaCl, 10 mM MgCl2 for 3 h at 4°C. The mixture was then purified using
GSTrap 4B columns on the ÄKTA start protein purification system. The bound complex
GSTACK-CDC42 was eluted with 10 mM reduced glutathione (in 20 mM Tris, pH 8.0).
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Ten percent of 100 % trichloroacetic acid (TCA) solution was added to precipitate the complex.
After TCA precipitation, 8M urea was added to the protein sample and was analyzed on a 15%
SDS-PAGE.
Intrinsic Fluorescence Quenching
Fluorescence titration of CDC42 and ACK by ZCL278 was carried out by monitoring the change
of fluorescence intensity of tryptophan of CDC42 and ACK upon ZCL278 binding. Fluorescence
measurements were collected using a fluorescence Spectrophotometer F-2500 (Hitachi) equipped
with a slit width set to 2.5 nm. Measurements of intrinsic fluorescence of CDC42 and ACK were
performed using an excitation wavelength of 280 nm and emission intensity was recorded from
300 nm to 450 nm. Both titration experiments were performed using a fixed concentration of
CDC42 (10 µM) and ACK (10 µM) placed in a quartz cuvette which was titrated by the addition
of 15 µM ZCL278 at each titration. All experiments were conducted in triplicate in 1X PBS, 10
mM Mgcl2, pH 8.0. Samples in the cuvette were mixed after each titration before taking the
reading.
Extrinsic Fluorescence Quenching
To better understand the molecular details on CDC42 regulation and its interaction with effector
proteins, fluorescence spectroscopic assays were performed. CDC42 was specifically labeled
with a fluorescent group, succinimidyl 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]hexanoate
(sNBD) (figure 2) which served as an extrinsic fluorophore for CDC42 binding interactions with
effector proteins [12]. Here, it was used to monitor the influence of ZCL278 on the CDC42-ACK
binding interaction. The labeling process was performed as previously described [13]. Briefly,
CDC42 was incubated with sNBD at a 1:15 ratio for 1 h at room temperature on a rocker.
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Unbound sNBD was removed by centrifugation, dialysis, and desalting with a PD-10 column.
SNBD, with excitation and emission wavelength of 488 and at 545 nm, respectively [12], is
covalently attached to Lysine150 on CDC42 [12] (figure 4). Once labeled, sNBD-CDC42
complex displays fluorescence change upon binding to an effector protein, which can be used to
monitor the binding interaction between CDC42 and ACK [12]. Consequently, a control
experiment was performed as follows :70 nM of sNBD-CDC42 was titrated with an increasing
amount of ACK. The final concentration of ACK in the cuvette varied from 0 nM to 2 μM. Then
5 μM of sNBD-CDC42 incubated with 5 μM of ZCL278 was titrated with 2.5 mM ACK at a
time as the continuous quenching of the fluorescence was monitored.

Figure 3. sNBD covalently attached to CDC42 at Lysine 150
The Kd of both experiments were calculated by nonlinear least squares and fit to the equation:
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Where F represents the change in fluorescence over the initial fluorescence (ΔF/Fo); Fi
represents the initial value of ΔF/Fo; Ff represents the final value of ΔF/Fo; Lt is the total
concentration of ACK, and Rt is the total concentration of CDC42. The fluorescence intensity
was measured using a SLM 8000c spectrofluorometer operated in the photon-counting mode. All
experiments were performed in triplicates in 20 mM Tris, 100 mM NaCl, 10 mM Mgcl2, pH 8.0.
Isothermal Titration Calorimetry (ITC)
ITC is a technique used to quantitatively study biomolecular interactions. It consists of binding
two biomolecules where one is placed in the syringe and the other one in the cell. It operates by
measuring the amount of heat released or absorbed during the binding experiment.
By measuring the heat transfer, ITC provides the thermodynamic profile of the molecular
interaction consisting of the binding constants (Kd), reaction stoichiometry (n), enthalpy (∆H)
and entropy (ΔS). In our lab, this technique was used to probe the influence of ZCL278 of
thermodynamic profile of CDC42/ACK interaction. The experiment was performed in a
MicroCal iTC200 at 25 °C. Lyophilized CDC42 and ACK were dissolved in 10 mM phosphate
buffer pH 8.0, 100 mM NaCl, 10 mM MgCl2, 0.5 mM TCEP, 1 % DMSO. A concentration of
16 μM of CDC42 (placed in the cell) was titrated by 181 μM of ACK placed in the syringe. The
CDC42-ZCL278 complex for formed by incubating 16 μM CDC42 with 33 μM ZCL278 right
before the experiment. The CDC42-ZCL278 complex was placed in the cell and was titrated
with 181 μM ACK placed in the syringe. A volume of 1 μL of 100% DMSO was added to the
ACK sample to prevent buffer mismatch. The titration consisted of 30 injections with 1.3 μL of
the titrant (ACK) injected at each injection. A blank run was performed in which CDC42 was
replaced with the buffer and was titrated by ACK.
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Another blank run was performed in which ZCL278 was added to the buffer placed in the cell
with no CDC42 and was titrated by an ACK sample in which was added an appropriate amount
of DMSO to avoid buffer mismatch. The data were fitted to an equation describing binding at a
single site, using the Origin software supplied to provide estimates of the thermodynamic profile
of the interaction including Ka, ΔH, and the apparent stoichiometry of interaction.
Far-UV Circular Dichroism (CD)
Far-UV CD calculations were performed using a Jasco J-1500 CD spectrometer. Conformational
modifications in the secondary structure of individual proteins (CDC42, ACK), protein-small
molecule complexes (CDC42-ZCL278, ACK-ZCL278), and protein-protein-small molecule
complexes (CDC42-ACK, ACK-CDC42-ZCL278) were analyzed in the Far-UV region between
190 to 250 nm. A concentration of 50 μM for each protein (CDC42, ACK) was used in all
experiments which were performed in PBS, 0.27mM KCl, 0.18mM KH2PO4, 1.5mM
Na2HPO4, 13.7mM NaCl, 10 mM MgCl2, pH 8.0 in a 1-mm pathlength quartz cuvette. The scan
speed, band width and data pitch were respectively set to 50nm/min, 1.00nm/min and
0.1nm/min. All scans were performed in triplicate and averaged to obtain the final CD spectra.
All individual spectrum was subtracted from the resulting complex spectra so the final difference
spectrum could be obtained.
Results
ZCL278 Influence on non-complexed CDC42 and ACK fluorescence quenching
Before ACK/CDC42 interaction experiments were performed, it was important to ascertain that
ZCL278 only binds to CDC42 and not to ACK.
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To this end, a tryptophan fluorescence quenching experiment involving CDC42 and ACK
individually in the presence of ZCL278 was conducted. As can be shown from figure 4A, ACK
tryptophan fluorescence remained unchanged during the titration, which can be explained by the
fact the switch I region in the CDC42 has very little similarity to the ACK CRIB region which is
where these two proteins interact. However, ZCL278 quenched CDC42 tryptophan fluorescence
and caused CDC42 tryptophan maximum fluorescence absorption to shift from 320 when
tryptophan finds itself a non-polar environment to 355 nm when it is now exposed to polar
environment as can be seen on figure 4B. Overall, figure 3 shows that ZCL278, by binding to
CDC42, caused structural modifications in CDC42 leading tryptophan from being buried in an
hydrophobic microenvironment to being exposed to the outer hydrophilic environment of the
protein indicating a binding interaction. ZCL278 quenching action on CDC42 suggests the
formation of hydrogen bonds between CDC42 Thr35 and NH groups of ZCL278. Once CDC42
Thr35 H-bonds with ZCL278 NH groups, given the importance of Thr35 in the protein stability,
it undergoes conformational changes which end up changing tryptophan microenvironment,
thereby quenching its fluorescence intensity. This is a very useful technique used in protein
biochemistry to monitor protein-protein interaction (provided that one protein is tryptophan-free)
and protein-SMI interaction. Our fluorescence quenching data for CDC42 are consistent with
those published by Friesland et al. [10] where they quenched tryptophan fluorescence with
ZCL278 to determine the binding affinity of CDC42-ZCL278 binding interaction.
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Figure 4. Tryptophan Fluorescence quenching of ACK and CDC42 by ZCL278. A) ACK
tryptophan fluorescence remained unchanged B) CDC42 tryptophan maximum
fluorescence absorption shifted from 320 nm to 355 nm.
ZCL278 influences CDC42:ACK binding
Since CDC42 binds to ACK with nanomolar affinity [10], an in vitro binding assay was
conducted to probe the direct impact of ZCL278 on the CDC42-ACK interaction. As it is shown
in figure 5A, in the presence of ZCL278 (+ZCL278) (lane 3) there is less CDC42 compared to
the one with no ZCL278 (lane 2). Using the UN-SCAN-IT gel 7.1 software, figure 5B depicts
graphically how CDC42-ACK binding decreased in the presence of ZCL278. During the
incubation of CDC42 with GSTACK, only 15% of the CDC42 binds to GSTACK. However, up
to 10% of CDC42-ZCL278 binds to GSTACK. This decrease in binding suggests that when
ZCL278 is incubated with CDC42, key hydrophobic and ionic interactions occur between
CDC42 Phe28 and the aromatic rings of ZCL278, and between Thr35, Thr43 and ZCL278 NH
groups. As a result, since these key residues in CDC42 such as Thr35 and Thr43 and the
aromatic rings are also important for non-covalent interactions between CDC42 and ACK, ACK
can no longer bind to CDC42 effectively due to the “unavailability” of these key residues to
establish the bonds, which leads to a reduced binding.
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Figure 5. A) In-vitro binding assays comparing the binding affinities between GSTACK/CDC42 in the presence/absence of ZCL278. In the presence of ZCL278 (lane 3), there
is a decreased binding of CDC42 (20KDa) to GST-ACK (31KDa) characterized by a scant
amount of CDC42 in the +ZCL278. The concentration of ZCL278 used was 50 μM. B) A
graphical depiction of the In vitro binding assays using UN-SCAN-IT gel 7.1 software.
Fluorescence spectroscopy shows reduced CDC42:ACK binding affinity in the presence of
ZCL278
As stated earlier, CDC42-ACK binding affinity is in the nanomolar range [29,30]. It has been
reported that sNBD fluorescent property can be used to monitor CDC42 interactions with its
effectors [12]. To probe a possible influence of ZCL278 on the CDC42-ACK binding affinity,
we conducted fluorescence spectroscopy using an extrinsic fluorescent reporter group covalently
attached to the side chain amine of Lys150 on CDC42 (figure 2). Figure 6 depicts a sNBDCDC42-ACK binding control experiment which shows a binding affinity (Kd) value of 200 nM
(figure 6). In the presence of ZCL278 the Kd value increased to 1.6 μM as shown in fig 5B. The
Kd value for our CDC42-ACK binding experiment is in the nanomolar range consistently with
published Kd values for CDC42 and ACK [13]. This decrease in CDC42-ACK binding affinity
suggests that the switch I is unavailable since ZCL278 occupies it by forming CDC42-ZCL278
complex, and that key residues such as Thr35 and Thr43 as well as several hydrophobic residues
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like Phe28 located in the switch I are no longer available for non-covalent interactions between
CDC42 and ACK.

Figure 6. sNBD fluorescence titration of CDC42 with ACK. (A) In the absence of ZCL278,
CDC42 binds to ACK with a Kd value of 200 nM. (B) In the presence of ZCL278, the
binding affinity between CDC42 and ACK diminished with an increased Kd value of 1.6
μM.
ZCL278 decreased CDC42-ACK binding affinity in isothermal titration calorimetry
ITC was used to monitor the influence of ZCL278 on the CDC42-ACK protein-protein
interaction. Experiments first involved the titration of CDC42 with ACK, an apparent Kd value
of 600 nM was calculated. In the second set of experiments, CDC42-ZCL278 complex was
titrated with ACK and a Kd value of 4 μM, nearly 7-fold increase of the Kd calculated for the
experiments in the absence of ZCL278 as shown in figure 7. The Kd value for our ITC from the
CDC42-ACK binding experiment is very close to the one we got from our fluorescence
quenching experiment. This reduced binding affinity between CDC42 and ACK in the presence
of ZCL278 is consistent with our previous data and suggests that the switch I is occupied by
ZCL278, and several key residues in the switch I are longer available to establish non-covalent
interactions between CDC42 and ACK.
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Figure 7. Isothermal titration calorimetry of CDC42 with ACK. (A) In the absence of
ZCL278, CDC42 binds to ACK with a Kd value of 600 nM. (B) In the presence of ZCL278,
the binding affinity between CDC42 and ACK diminished with an increased Kd value of 4
μM.
CD spectroscopy revealed major structural changes caused by ZCL278 to CDC42-ACK
interactions
Far-UV circular dichroism (CD) is a technique used to investigate the secondary structure of
chiral macromolecules such as proteins or non-chiral molecules in a chiral environment. To this
end, far-UV CD was used to probe structural modifications that occurred in the CDC42
secondary structure upon ZCL278 and ACK binding to CDC42. Far-UV CD spectra of CDC42
(figure 8A) shows a negative peak at around 210 nm along with a deeper peak at 220 nm, which
is characteristic of secondary structure with an α-helix prevalence. Upon binding of ZCL278,
changes in the structure of CDC42 occurred which led to a change from an α-helix dominated
secondary structure to a more disordered structure (figure 8B) and even more disordered upon
ACK binding to the ZCL278-CDC42 complex (figure 8C). However, a secondary structure with
a prevalence of β-sheets was observed upon ACK binding to CDC42 (figure 8D) suggesting that
ZCL278 binding to CDC42 really interferes with CDC42-ACK interaction by causing such
contrasted secondary structural modifications between CDC42-ACK and ZCL278-CDC42-ACK
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complexes. Figures 8E and F show that ACK adopts a random coil secondary structure in the
presence and absence of ZCL278. Thr35 is key in maintaining the stability of CDC42. When
ZCL278 NH groups H-bond with Thr35, it apparently destabilizes CDC42 overall structure
which most likely caused the secondary structure to change from a well-defined secondary
structure to a random coil. The binding of ACK to the CDC42-ZCL278 complex leads to the
disappearing of the α-helix portion and to more disordered structure, which suggests that we are
dealing with 3-component complex with no defined secondary structure. The lack ofinfluence of
ZCL279 showed in the ACK CD spectrum suggests that ZCL278 did not interact with ACK and
as a result has no influence on its secondary structure. It also suggests that the CRIB region in
ACK has no affinity for ZCL278.

Figure 8. Circular dichroism difference spectral data for CDC42 in the presence and
absence of ZCL278 and ACK. Binding of ACK and ZCL278 to CDC42 induced major
secondary structure differences.
Discussions
ZCL278, as displayed in our data, impeded CDC42-ACK interaction and caused CDC42
structural modifications upon binding. This suggests that ZCL278 must be probed and explored
further on downstream proteins like Wasp and PAK, and other proteins taking part in regulating
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the cycle including GEFs and GAPs for acquisition of detailed molecular knowledge regarding
the strength and selectivity of the drug candidate. Data gathered from the in vitro binding assay
indicated that ZCL278 incubation with CDC42 led to 5 % decrease in the capacity of ZCL278CDC42 complex to bind to ACK. Given CDC42 binds to ACK with low nanomolar affinity and
binds to ZCL278 with low micromolar affinity, this is quite significant. In addition, given the
concentration of CDC42 in the experiment was much higher relative to that of the ZCL278, a
reduction of 5% in the binding capacity is quite noteworthy. The incubation of ZCL278 with
CDC42 caused the binding affinity to decrease tenfold based on data from fluorescence
spectroscopy and isothermal titration experiments. Protein-protein interactions and proteinprotein-SMI experiments are usually laden with issues. These problems range from small
molecule is not water soluble, protein aggregates in the appropriate solvent of the small
molecule, to adding disulfide bond breaker like TCEP to optimize binding which in turn disturbs
the complex formation and even changes the sample pH. Therefore, accurately determining the
Kd from fluorescence quenching and isothermal titration calorimetry experiments was very
difficult. However, the closeness of Kd values obtained from triplicate experiments increases the
accuracy of our data. Nonetheless, structural modifications should be done on ZCL278 to make it
more hydrophilic so it can behave better in aqueous environment which is a better mimic of the
cytosol.
The interaction between CDC42 and ACK determined by these key residues, Ala41, Val42,
Thr43, Gly47, Thr52, Phe56, and Leu174, with Ala41, Val42, Thr43, Gly47 in the switch I
region [1]. It was predicted that ZCL278 would H-bond with Thr35, Asn39, and Ap57 of CDC42
(figure 1) and hydrophobically interact with Val36 and Ph56. It is most likely that ZCL278
disturbs CDC42-ACK interaction by H-bonding with Thr35 and Thr43 and hydrophobic bonds
77

with Ala41, Val42, Gly47 in the switch I, which in turn disturbed the CDC42-ACK binding
complex formation. More probing and exploratory work should be conducted on ZCL278
including NMR spectroscopy and molecular dynamics simulation, which should reveal to be
paramount in unveiling molecular details explaining ZCL278 interference with CDC42-ACK
interactions. Co-transfecting CDC42 and ACK into Cos-alpha cell lines and studying their
transgenic expression and interaction in the absence and presence of ZCL278 should be
particularly useful. That would unveil key knowledge on how ZCL278 influences the binding of
CDC42 to ACK in eucaryotic cells, which would a better reflection of what would happen in
human cell scenario, which could provide important insights into the efficacy of ZCL278 as a
drug in humans. So far, no in vitro research involving CDC42, and ACK has been conducted. So,
studying the transgenic expression of these two genes in vitro in relation to ZCL278 would
reveal much.
Conclusion
Overall, our data suggest that ZCL278 interferes with the CDC42-ACK binding interaction. It
does so most likely by binding to CDC42 switch I region which in turn interferes with CDC42ACK binding. Much remains to be known about ZCL278 interference with the direct binding of
CDC42 to ACK. Despite major disadvantages that ZCL278 suffers from, it has helped showed
once again the necessity of finding small molecules inhibitors more potent and more selective to
specifically target Ras superfamily of proteins individually, which will ultimately aid in tackling
more effectively Ras-driven cancers.
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CHAPTER THREE:
Characterizing CDC42 and CDC42F28L in the presence of the small molecule inhibitor ZCL278
Abstract
The Ras superfamily of small GTPases are involved in cell-signaling processes that, if not
regulated, may lead to continued cell multiplication, inhibited apoptosis, and cell transformation.
They work as molecular controllers, which via GTP/GDP exchange cycles, modulate cellular
activities by switching them on and off. Many mutations have been identified in Ras proteins
which prevent GTP hydrolysis and irreversibly keep the GTPase trapped in the ‘on’ (GTPbound) state, and transformed several cell types and have been found in up to 40% of all human
tumors. Other Ras-related GTPases, including members of the Rho subfamily, have been
involved in cell growth regulation. Particularly, CDC42 is one those Rho members that has
recently received a great deal of attention. CDC42 is involved in the regulation of many cellular
processes including cell adhesion, mitosis, and cytoskeletal rearrangements. Evidence shows that
CDC42 hyperactivation leads to cell transformation as revealed in studies conducted on the ‘fastcycling’ CDC42 mutants which are able of constitutive nucleotide exchange, but still exhibit full
GTP hydrolytic activity [1]. One example of this so-called ‘fast-cycling’ CDC42 mutant is
CDC42F28L. The CDC42F28L variant can do GDP/GTP exchange rapidly, thereby greatly
increasing the cytoplasmic pool of activated CDC42 resulting in oncogenic activities. It is
imperative that the biophysical parameters of this mutant be studied so that drugs can be
designed to stop its oncogenic behavior. ZCL278 is a selective inhibitor of CDC42. It binds
directly to CDC42 and disturbs its functions. This work aimed at characterizing CDC42 and
CDC42F28L in the presence and absence of ZCL278.
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Overall, data from our experiments show that ZCL278 bound to both CDC42 and CDC42F28L
similarly with micromolar affinity, and that ZCL278 induced conformational modifications in
CDC42 and CDC42F28L upon binding and rendered CDC42 and CDC42F28L more thermally
stable.
Introduction
The Ras superfamily of G proteins is implicated in several cellular activities such as cell
division, protein trafficking, cytoskeletal rearrangements, and secretion. These GTPases are
regulated by shuttling between the biologically active GTP form and the inactive GDP-bound
form [1, 2]. Due to their intrinsic GTP hydrolysis capacity, these small GTPases hydrolyze GTP
to GDP. This GDP-GTP cycle is controlled by a variety of regulatory proteins such as GDI,
GEF, and GAPs [3-5]. The Ras proteins have been the object of considerable investigation due to
their potential oncogenic capacity. Oncogenic Ras proteins induce cell transformation as a result
of either a constitutively active GTPase or an increase in the rate of GTP/GDP shuttling, which
ultimately leads to an increased downstream kinases activity. Several mutations in Ras proteins
that inhibit their GTPase activity have been involved in several cancers [6-8]. For instance, a
mutant protein which results from the replacement of phenylalanyl 28 with leucine
(CDC42F28L) in CDC42 wild-type causes cell transformation due to the increased rate of
cycling between the active and inactive forms of the mutant protein [7]. The CDC42F28L
mutation which led to cell transformation is comparable to the one induced by the oncogenic
protein Dbl, which catalyzes fast GTP/GDP exchange in CDC42. Phenylalanyl 28 mainly
stabilizes the nucleotide by strongly interacting with the aromatic ring of the attached nucleotide
[10,13,14].
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Since ZCL278, a selective inhibitor of CDC42, was shown in our previous binding experiments
to influence CDC42/ACK interaction, we characterized CDC42 and CDC42F28L in the absence
and presence of ZCL278 in this current work. DSC data suggest that ZCL278 made CDC42 and
CDC42F28L more thermally stable while heat-induced denaturation data did not reveal any
noticeable change in the denaturation pattern caused by heat in the presence and absence of
ZCL278. Fluorescence quenching data suggest that there was no change in the quenching pattern
of CDC42 and CDC42F28L in the absence and presence of ZCL278. Urea-induced denaturation
showed no difference in the denaturation pattern of CDC42 in the presence and absence of
ZCL278. While in the presence of ZCL278, CDC42F28L showed a two-state denaturation
process, CDC42F28L showed a three-state denaturation in its absence. Our intrinsic GTPase
nucleotide exchange data showed that ZCL278 had no influence on the CDC42 and CDC42
intrinsic GTP/GDP exchange.
Materials and Methods
Protein constructs
CDC42 and CDC42F28L were expressed in pET-15b vectors as 6His-tag fusion proteins.

Figure 1. Amino acid sequence of CDC42 (A) and that of CDC42F28L (B) with a single
point mutation in red.
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Recombinant protein expression
Escherichia coli BL21 cells were used to express recombinant proteins. Seed cultures expressing
CDC42 and CDC42F28L were diluted in fresh 2TY growth medium (1:10) and grew to OD600
0.5-0.8 at 37 °C. Upon reaching the desired OD600, they were induced with isopropyl-β-d-1thiogalactopyranoside (IPTG) (0.5 mM) for 4 hours. Proteins were purified by affinity
chromatography with Histrap FF column (GE Healthcare) on the ÄKTA start protein purification
system (GE Healthcare). Upon purification, CDC42 and CDC42F28L were dialyzed in PBS pH
8.0. Protein concentrations were measured by using the extinction coefficient of each protein.
Purity of proteins was verified with SDS-PAGE.
Nucleotide exchange
CDC42 as well as CDC42F28L is overexpressed in its GDP-bound, inactive state. CDC42 then
undergoes nucleotide exchange (GDP/GTP exchange) using GTP analog (β,
γMethyleneguanosine 5′-triphosphate) (10X, CDC42; 20X, CDC42F28L) enough to
competitively displace GDP from nucleotide biding pocket. Briefly, GDP-CDC42 or GDPCDC42F28L were mixed with 5 mM EDTA and GTP analog (1:10 or 1:20 ratio) and incubated
on a rocker at 4 °C for three hours for CDC42 and six hours for CDC42F28L. GDP, EDTA and
the unbound GTP were removed with a PD-10 desalting column upon incubation. The pooled
protein was then detected with the Bradford reagent, combined into one sample to which was
added 10 mM MgCl2, lyophilized, and stored for downstream experiments.
ZCL278 solution preparation
ZCL278 was purchased from ApexBio Technology (cat #A8300) and prepared in 100% DMSO.
It was then aliquoted and stored at -20 °C.
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Intrinsic fluorescence quenching
Fluorescence measurements were collected using Jasco J-1500 CD spectrometer. Measurements
of intrinsic fluorescence of CDC42 and CDC42F28L in the presence of ZCL278 were performed
at a fixed excitation wavelength (280 nm) and emission intensity was recorded from 300 to 450
nm. All titration experiments were performed using a fixed concentration of CDC42 (2 µM) and
CDC42F28L (2 µM) placed in a quartz cuvette which was titrated by the addition of 20 µM
ZCL278 (1: 10 ratio) at each titration. ZCL278 showed absorbance at around 320 nm, so
correction was made by subtracting the ZCL278 fluorescence absorbance from those of the
proteins. All experiments were conducted in triplicate in PBS, 10 mM MgCl2, pH 8.0. Samples
in the cuvette were mixed by pipetting up and down after each titration and a 5-minute delay was
taken for sample equilibrium before taking the next reading. The excitation/emission bandwidth
and the data pitch were set to 5.0 nm/min, 10.0 nm/min, 1.0 nm/min, respectively. The Kd values
and fitting models were determined with the Hill equation on the Origin software.
Far-UV Circular Dichroism
Circular dichroism (CD) calculations were performed using a Jasco J-1500 CD spectrometer.
Conformational modifications in the secondary structure of individual proteins CDC42 and
CDC42F28L in the absence and presence of ZCL278 (10 µM) were analyzed in the Far-UV
region between 190 to 250 nm. A concentration of 50 µM of each protein (CDC42,
CDC42F28L) was used in all experiments which were performed in PBS, 0.27mM KCl, 0.18mM
KH2PO4, 1.5mM Na2HPO4, 13.7mM NaCl, 10 mM MgCl2, pH 8.0 in a 1-mm pathlength
quartz cuvette. The scan speed, band width, and data pitch were respectively set to 50nm/min,
1.00nm/min and 0.1nm/min. All CD measurements were performed in triplicate and all scans
were accumulated three times to obtain the final averaged CD spectra.
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All individual spectrum was subtracted from the resulting complex spectra so the final difference
spectrum could be obtained.
Differential scanning calorimetry
Heat-induced denaturation of CDC42 and CDC42F28L in the presence of ZCL278 was
performed with MicroCal DSC (Malvern). CDC42 and CDC42F28L (50 µM) was dialyzed in
PBS, 10 mM MgCl2, pH 8.0, at 4°C. Samples were heated from 25 to 90 °C using a scan rate of
1.5 °C/min. Buffer samples without protein were run prior to the experiment to serve as baseline
and were subtracted from the protein scan. All DSC experiments were done in triplicate. The
melting curve was constructed, and the Tm value determined by the DSC machine.
Urea denaturation using CD spectroscopy
Urea denaturation measurements were performed using CD spectroscopy with the Jasco J-1500
CD spectrometer which is equipped with a cell holder capable of rotation. This instrument is also
equipped with an automatic titration unit suitable for urea denaturation. CDC42 and
CDC42F28L was dialyzed in PBS, 0.27mM KCl, 0.18mM KH2PO4, 1.5mM Na2HPO4,
13.7mM NaCl, 10 mM MgCl2, pH 8.0 in a 1-mm pathlength quartz cuvette. CDC42 or
CDC42F28L (50 µM), with or without ZCL278 (10 µM), was placed in the cell, and urea (8M)
was placed in the syringes. The scan speed, band width, and data pitch were respectively set to
50 nm/min, 1.00nm/min and 0.1nm/min.
The titration was set up into 40 injections with 0.2 µM of urea added at each titration. All
measurements were performed in triplicate. Denatured fractions were plotted as a function of
urea concentration.
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Fractions of unfolded proteins were calculated using the equation:

where Fd is the fraction of unfolded protein, MEx is the second absorbance of the folded protein,
MEi is the first absorbance of folded protein, and MEF is the last absorbance of the unfolded
protein. The curves were constructed by plotting the fraction of unfolded protein as a function of
urea concentration.
Temperature denaturation using CD spectroscopy
Temperature denaturation experiments were done by CD spectroscopy using Jasco J-1500 CD
spectrometer equipped with a variable temperature cell holder. CDC42 or CDC42F28L (50 µM)
was dialyzed in PBS, 0.27mM KCl, 0.18mM KH2PO4, 1.5mM Na2HPO4, 13.7mM NaCl, 10
mM MgCl2, pH 8.0 in a 1-mm pathlength quartz cuvette. Experiments were done with CDC42
or CDC42F28L in the presence and absence of ZCL278 (10 µM). The scan speed, band width,
and data pitch were respectively set to 50 nm/min, 1.00nm/min and 0.1nm/min, and temperature
was raised from 25 to 90 °C with a scan speed of 1.5°C/min, and a temperature interval of 5 °C.
Denatured fractions were plotted as a function of temperature. Fractions of unfolded proteins
were calculated using the equation:
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where Fd is the fraction of unfolded protein, MEx is the second absorbance of the folded protein,
MEi is the first absorbance of folded protein, and MEF is the last absorbance of the unfolded
protein. The curves were constructed by plotting the fraction of unfolded protein as a function of
temperature.
Intrinsic GTP hydrolysis assay
Intrinsic GTP hydrolysis assays were performed to probe the intrinsic GTPase activity of CDC42
and CDC42F28L in the presence of ZCL278, and were performed according to the kit
manufacturer, Promega. Briefly, GDP-CDC42 and GDP-CDC42F28L (3.5 μM each) (with or
without ZCL278 (5 µM)) was added to a GAP buffer (from kit) and was mixed with 5 μM of
GTP and 1 mM DTT to initiate the GTP hydrolysis. After 3 hours for CDC42 and 0.5 hour for
CDC42F28L, reagents from the kit was added to the reaction mix and was incubated for 30
minutes upon which time a detection reagent was added to the mix and was incubated for 10
more minutes after which period the luminescence was measured using the Synergy H1 Hybrid
Multi-Mode Reader.
Results
ZCL278 binds to CDC42 and CDC42F28L with micromolar affinity
In protein biochemistry, fluorescence spectroscopy is used to monitor protein (un)folding, and to
probe protein conformational modifications and binding interactions. To calculate the binding
affinity of ZCL278 to CDC42 and CDC42F28L, a tryptophan fluorescence quenching
experiment was performed. ZCL278 caused tryptophan fluorescence quenching in both proteins
in a similar manner as shown in figure 1.

87

Curve fits and Kd values for CDC42 and CDC42F28L were calculated using the equation
already described in the method section. Molecular dynamics simulation data from our lab
showed that ZCL278 most likely binds to CDC42 at the switch I region by establishing noncovalent interactions between CDC42 Thr35 and ZCL278 NH groups. Each titration causes
intermolecular changes leading to conformational changes that trigger little changes in
tryptophan residue microenvironment resulting in fluorescence quenching. The titration was
carried out until the fluorescence was quenched. These close kd values highlight the very little
structural differences between CDC42 and CDC42F28L since Ph28 is not essential for CDC42
overall secondary structure. Various binding experiments involving the direct binding of a small
molecule inhibitor to a Ras protein provided Kd values in the low micromolar range, which is
consistent to our Kd values that are also in the low micromolar range. This low binding affinity
trend highlights the challenges in finding a potent small molecule inhibitor that can bind Ras
proteins with binding affinity in the low nanomolar range. With such tight binding, this small
molecule inhibitor will be more likely able to compete with Ras-effector tight binding
interactions which will result in a small molecule inhibitor that will more likely become a drug
that can effectively tackle Ras-related cancers.

Figure 2. Fluorescence titration of CDC42 and CDC42F28L with ZCL278. Both proteins
bind to ZCL278 with micromolar affinity.
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Far-UV CD shows ZCL278 caused structural changes in CDC42 and CDC42F28L
Far-UV circular dichroism is a technique used to investigate the secondary structure of optically
active macromolecules such as proteins. To this end, far-UV CD was used to explore structural
modifications that could occur in the CDC42 secondary structure as a result of the introduction
of the single point mutation and upon binding of CDC42 and CDC42F28L to ZCL278. Far-UV
CD spectra of CDC42 (figure 3A) shows a negative peak at around 210 nm along with a deeper
peak at 220 nm, which is characteristic of secondary structure with an α-helix prevalence. Figure
3B shows that the secondary structure of the mutant remained nearly unchanged with, however,
contrary to the wild-type spectra, the mutant spectra show a steeper positive peak at 210 nm and
a deeper negative peak at 210 nm. This is characteristic of a secondary structure with a
dominance of α-helix and some β-sheets. Upon binding of ZCL278, changes in the structure of
CDC42 occurred which led to a shift from α-helix to a disordered secondary structure with some
α-helix (figure 3C). The same trend is observed in figure D where the addition of ZCL278
changed the CDC42F28L secondary structure dominated by α-helix- to a possible combination
of β-sheets and disordered segments.
Molecular dynamics simulation data gathered from our lab (unpublished data) and by Friesland
et al. suggest that ZCL278 most likely binds to CDC42 at the switch I region by establishing
non-covalent interactions between CDC42 Thr35 and ZCL278NH groups. Through these noncovalent interactions, ZCL278 induced conformational changes in CDC42 secondary structure
which result in a more disordered structure in both wild-type and mutant. The mutation caused
the CDC42F28L variant to have a lower percentage of α-helix which can be shown by the
negative peak which tends more towards the 210 nm mark than the 220 nm mark.
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Figure 3. Far-UV CD of CDC42 and CDC42F28L in the presence of ZCL278. Both proteins
underwent changes from an α-helix- to a β-sheet-dominated secondary structure upon
binding to ZCL278.

CDC42 and CDC42F28L became more thermally stable in the presence of ZCL278 in DSC
DSC is a technique used to probe the thermal stability of macromolecules such as proteins. In
our case, we investigated the thermal stability of CDC42 compared to CDC42F28L as well as
their thermal stability in the presence of ZCL278. Overall, the apparent Tm of CDC42, 62 ± 0.5
°C, remained seemingly unchanged compared to that of CDC42F28L, 64 ± 0.8 °C (figure 4).
However, both wild-type and mutant became thermally more stable in the presence of ZCL278.
The increase in the thermal stability of the wild-type and the mutant would suggest that the small
molecule inhibitor shields CDC42 and CDC42F28L switch I region by establishing non-covalent
bonds (ionic and hydrophobic) between CDC42 Thr33 and ZCL278 NH groups. The Tm
obtained in the DSC experiment is consistent with Tm published from our lab [15]. The Tm
obtained for the CDC42F28L thermal denaturation is very close to that of the wild type. This is
not surprising and would suggest that the mutation does not cause much change in CDC42
secondary structure.
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Figure 4. DSC thermograms of CDC42 and CDC42F28L in the presence of ZCL278. The
apparent Tm of CDC42 remained unchanged compared to that of CDC42F28L while wildtype and mutant became thermally more stable in the presence of ZCL278.
CD spectroscopy shows a two-state urea-induced unfolding of CDC42F28L in the presence of
ZCL278
Urea-induced unfolding using CD spectroscopy is a technique used to monitor the structural
changes occurring in the secondary structure of a protein in the presence of an increasing amount
of urea. In our case, we monitored the unfolding of CDC42 and CDC42F28L in the presence of
an increasing concentration of urea using CD spectroscopy. A 3-state unfolding process was
observed. For CDC42 in the absence and presence of ZCL278, in the first state CDC42 remained
folded from 0 to 2.4 µM of urea. A second state was observed between 2.4 and 5. 8 µM, after
which the protein completely unfolded and stayed so until the addition of last urea injection
(figure 5). A 2-state unfolding process was observed for CDC42F28L in the presence of ZCL278.
CDC42F28L secondary structure remained folded from 0 to 2.4 µM, starts unfolding from 2.4 to
5.8 µM, and completely unfolded and remained so from 6 to 8 µM. Surprisingly, in the presence
of ZCL278 the protein appeared to have already been in an “intermediate state” right at the onset
of the titration and remained in that state from 0 to 5.8 µM, then completely unfolded from 5.8 to
8 µM. Urea-induced denaturation based on CD spectroscopy did not suggest an impact of the
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small molecule inhibitor on the denaturation of wild-type. It is unclear why this is the case, and
more research should be done to unveil the reason for the ineffectiveness of the small molecule
inhibitor in protecting CDC42 from being denatured by urea. Interestingly, CDC42F28L variant
displays a two-state urea-induced denaturation in the presence of ZCL278. This result would
suggest that the drug destabilizes the variant and causes it to denature faster by urea. This is a bit
contradictory to what we have seen so far, so more research needs to be done towards elucidating
those data.

Figure 5. Urea-induced unfolding of CDC42 and CDC42F28L in the presence or absence of
ZCL278. No significant difference was observed in the urea-induced unfolding of CDC42 in
the presence of ZCL278. In the presence of ZCL278, a 2-step unfolding was observed for
CDC42F28L compared to a 3-step unfolding observed in the absence of ZCL278.
CD spectroscopy shows no change in heat-induced unfolding of CDC42 and CDC42F28L in the
presence of ZCL278
Temperature-induced unfolding using CD spectroscopy is a technique used to monitor the
structural changes occurring in the secondary structure of a protein by heating the sample. In our
case, we monitored the unfolding of CDC42 and CDC42F28L in the presence of ZCL278 by
heating the protein samples from 25 to 90 °C using CD spectroscopy. A 3-state unfolding
process was observed for both proteins (wild-type and mutant) in the absence and presence of
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ZCL278. The proteins remained folded from 25 to 45 °C, started unfolding from 45 to 73 °C,
then completely unfolded from 73 to 90 °C. These heat-induced denaturation experiment data
suggest that the wild type and the mutant are heat-denatured in a similar pattern and that the SMI
has no influence on CDC42 and CDC42F28L heat-induced denaturation. Those denaturation
experiments either by urea or by heat are done based on CD spectroscopy at 220 nm. This
wavelength is where the negative peak is at for a CDC42 or CDC42F28L in a CD spectrum,
which indicates the prevalence of alpha helix in the secondary structure of the wild type and the
mutant. Whether or not the selection of this wavelength has to do with the incapacity of the
experiment to reveal the impact of the SMI on the proteins, that is beyond my knowledge and
perhaps urea- and heat-induced denaturation experiments based on fluorescence spectroscopy
would reveal more about the influence of the small molecule inhibitor on the CDC42 and
CDC42F28L variant denaturation experiments. Perhaps this has to with the way the circular
dichroism displays or records protein denaturation. I really do not know.

Figure 6. Temperature-induced unfolding of CDC42 and CDC42F28L in the presence or
absence of ZCL278. No significant difference was observed for either protein in the
presence of ZCL278.

93

Intrinsic GTP hydrolysis of CDC42 and CDC42F28L remained unchanged in the presence of
ZCL278
The GTPase-Glo assay kit is used to monitor the intrinsic, GAP-induced, or GEF-induced GTP
hydrolysis activity of a GTPase by measuring the amount of GTP left at the end of the hydrolysis
which is converted to ATP and is used to produce light (luminescence) by luciferase. A high
luminescence intensity means a slow-acting GTPase which hydrolyzes few GTP molecules
which results in a large amount of GTP left at the end of the reaction to be converted into ATP,
then eventually light (more light). A low luminescence signal means a fast-acting GTPase which
hydrolyzes a large amount of GTP resulting in very few molecules left at the end of the reaction
to be converted into ATP, then light (less light). In our case, we studied the influence of the small
molecule ZCL278 on CDC42 and CDC42F28L intrinsic GTP hydrolysis activity.
No significant difference was observed for CDC42 and CDC42F28L GTP hydrolysis activity in
the presence of ZCL278 (figure 7). The apparent lack of influence of ZCL278 on
CDC42/CDC42F28L intrinsic GTP/GDP exchange would suggest that ZCL278 does not bind at
the nucleotide binding site, as it is already known, and therefore has no impact on the GTP/GDP
exchange. It could also suggest the incapacity of ZCL278 to compete with the high affinity
between GTP and CDC42 and CDC42F28L.
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Figure 7. Intrinsic GTP hydrolysis of CDC42 and CDC42F28L in the presence of ZCL278.
Bar 1 represents the relative luminescence intensity of a negative control (no GTP); bar 2
represents the positive control (GTP with no GTPase). Bars 3 and 4 represent the GTPase
activity of CDC42 and CDC42F28L in the presence of ZCL278. No significant difference
was observed in the GTPase activity of either protein in the presence of ZCL278. This
figure is not comparing GTP hydrolysis activity of CDC42 and that of CDC42F28L which
take place in different timescales.

Discussions and Future studies
Data collected from CD spectroscopy experiments show that ZCL278 changed the secondary
structure of CDC42 and CDC42F28L with a prevalence of alpha helix into a random coil. The
Conformational modification may stem from the fact that the H—bond interactions between
Thr35 of CDC42 and the NH groups of ZCL278, which causes a destabilization of CDC42
structure since Thr35 residue has a crucial function in CDC42 conformational stability.
Moreover, through hydrophobic interaction between CDC42 Ph28 and the bulky rings of
ZCL278, ZCL278 can cause alterations in the 3D structure of CDC42 since, like Thr35, Phe28
contributes to the overall structural stability of CDC42.
Through its interaction with Phe28, Thr35, Thr43, Ala41, Val42, Gly47, ZCL278 has shielding
action on the switch I, Thr35 in particular, which is structurally very crucial for CDC42 stability,
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which led to an increased proteins stability as the DSC data show. There was not much difference
in the Heat- and urea-induced denaturation based on CD spectroscopy for CDC42 in the presence
and absence of ZCL278, except for a two-step urea-induced denaturation of CDC42F28L variant
compared to a three-step urea-induced denaturation for CDC42. More investigative work like
NMR and molecular dynamics simulation need to be explored which should unveil potential
mechanisms behind those findings. GTPase assays consisting of CDC42 and CDC42F28L
intrinsic nucleotide exchange did not display any noteworthy change in the nucleotide exchange
pattern either in the absence or presence of ZCL278. This results most likely from the binding of
ZCL278 to the switch I, which contributes very little in nucleotide exchange.
Conclusion
In summary, data from our fluorescence spectroscopy experiments show that ZCL278 bound to
both CDC42 and CDC42F28L with micromolar affinity and induced a red shift in both proteins
similarly. CD spectroscopy data showed that ZCL278 induced structural modifications in
CDC42 and CDC42F28L upon binding, and DSC data showed that ZCL278 rendered CDC42
and CDC42F28L more thermally stable. Urea-induced unfolding based on CD spectroscopy
suggests that in the presence of ZCL278 CDC42F28L unfolded in two stages. No noticeable
change in the heat-induced unfolding of CDC42 and CDC42F28L based on CD spectroscopy
was observed. Intrinsic GTPases activity assay showed that ZCL278 had no influence on the
intrinsic GTPases activity of CDC42 and CDC42F28L.
More studies including NMR spectroscopy studies need to be conducted to unveil molecular
details related to the way ZCL278 influenced some biophysical parameters of CDC42 and
CDC42F28L and why it had no influence on some other biophysical parameters. These data will
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be proved very useful in designing effective drugs with high and selective potency to combat
Ras-triggered cancers.
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CHAPTER FOUR: Conclusion and Future studies
Thus far we have discussed several strategic approaches by which Ras-induced cancers can be
tackled. One of them consists of interfering with the direct interaction between Ras proteins and
their downstream effectors. There are three ways that Ras-effector complexes can be targeted: 1)
targeting Ras proteins to change their conformational structures so they can no longer bind the
effectors effectively, 2) targeting the effectors to induce conformational changes so they can no
longer interact with Ras proteins, 3) targeting the Ras-effector complex. In this project, we
explored the strategy consisting of tackling the Ras protein directly and observing how Raseffector interaction differs from Ras-SMI-effector interaction. This is however a very difficult
approach given the tight binding between Ras proteins and their effectors, and the large proteinprotein binding surface between the binding partners [1], which has presumably halted any
progress in finding an effective small molecule inhibitor of Ras-effector complexes. This pattern
is no different from that of our findings even though we are dealing with Rho proteins. Our
binding experiments data suggest 1) a mere 5% decrease in CDC42-ACK binding in the presence
of ZCL278 even at a 50 µM concentration (protein concentration used was 200 µM), 2)
approximately a tenfold decrease in the binding affinity in the presence of 10 µM ZCL278 while
the concentration of CDC42 was 18 µM. Other notable direct Ras protein small molecules
inhibitors include ZCL367 which is more potent and more selective than ZCL278, CASIN which
binds CDC42-GDP with a 300nM affinity, NSC23766 which binds Rac1, a very close relative of
CDC42, with a 1.1 µM affinity, AZA1 and AZA197 which bind Rho proteins with low affinity
[2]. Although very little data relative to direct inhibition of the Ras-effector interactions are
available, through observation of the structure of those small molecule inhibitors (figure 1), it
can be predicted that the same low binding pattern will be observed, meaning the small
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molecules will not be able to compete with the effectors for binding to Ras proteins because of
their high binding affinity, which has been the issue in finding potent Ras proteins SMIs.

Figure 1. Comparison of the structures of several Rho protein SMIs. There is very close
structural resemblance between the ZCLs as they both target Ras protein switch I region.
CASIN targets a different region which is the nucleoside binding pocket, hence its
dissimilar structural resemblance compared to that of the ZCLs. NCS23766 and the AZAs
are both Rac1 direct inhibitors, which explains their similar structure and some structural
difference from the structures of the other two groups. Rac1 is the closest relative of
CDC42.
Another approach to tackle Ras-related cancers is to target Ras protein-effector interactions by
designing a small molecule inhibitor that can directly bind to the effectors. Such strategy has led
to the discovery of multiple inhibitors including rigosertib (figure 2) [3].

Figure 2. Structure of Rigosertib.
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This drug is presently in phase III clinical trials treating myelodysplastic syndromes. Even
though our goal was not to use ZCL278 to target the CRIB region of ACK, we nonetheless
conducted binding experiments between ZCL278 and ACK which ended up showing no binding
between these two, and by comparing the structure of ZCL278 to that of rigosertib, one can
easily see there is immense structural differences (figure 3).

Figure 3. Structure of Rigosertib (A) and ZCL278 (B)
Other small compounds have been reported to target Ras-effector interactions by binding directly
to the complex [4]. However, it was never proven that those compounds clearly bind to Ras
proteins or to the effectors or to the complex [4]. Another approach in the search of Ras-related
cancers therapy is to target the GTP/GDP cycle. Ras proteins shuttle between three distinct
states: a GDP-bound state, a transient nucleotide-free state, and a GTP-bound state that binds
directly to effector proteins. NMR spectroscopic studies showed that Ras displays distinct
conformational structures upon GTP binding [5]. In the inactive state, the switch I region adopts
an open conformation which facilitates nucleotide exchange and prevents effector binding. In the
transient state, the switch I has a closed conformation over the nucleotide that facilitates effector
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binding and GTP hydrolysis. When Ras proteins are in the nucleotide-free state, it has two
conformations: a T conformation and a R conformation. In the T conformation, Ras is
catalytically impotent whereas in the R conformation Ras is active [5].
It has been reported that inhibitors have been discovered which target different activation
conformations of Ras proteins [6], which led to the discovery of small molecule inhibitors like
Zn-cyclen [6], thiol-reactive compounds [7], and ARS-1620 (figure 4) [8].

Figure 4. Structure of ARS-1620
Structurally, these small molecules are very different and more complex than ZCL278, which
suggests why the intrinsic CDC42 GTP/GDP exchange assay that we conducted did not result in
any change in the presence of ZCL278. Although this is a very difficult approach given the
picomolar affinity with which Ras proteins bind to GTP and GDP, it has remained a very
promising strategy in the search for Ras-related cancers treatment thanks to new structural details
related to GTP-, and GDP- bound states of the Ras proteins that are revealed every year.
Direct binding interaction experiments between Ras superfamily of proteins and small molecules
inhibitors have been attempted and there has been interesting progress so far.
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Figure 5. Structural comparison of four SMIs that bind to Ras superfamily of proteins.
Although the GTP binding domain of Ras proteins are very conserved and all these SMIs
target the switch I region, they are quite different in size, shape, potency, and selectivity.
A small molecule called compound 3144 (figure 5A) has been found to bind KRAS with an 18
µM binding affinity [9]. This compound showed metabolic stability in liver microsomes and
anti-tumor activities in xenograft mouse cancer models [9]. BQU57 (figure 2B) is another small
molecule inhibitor that has been shown to preferentially bind to Ral GTPase over Ras and Rho
proteins with a binding affinity of 7.8 µM, thereby inhibiting the development of tumors [10].
Another small molecule inhibitor called NR1 (figure 2D) has been reported to directly bind to
Rheb at the switch II region and selectively prevents mTORC1 activation [11]. Although these
small molecule inhibitors are different in size and shape from ZCL278, they all however bind to
Ras proteins with low binding affinity regardless of their binding site. This pattern remains
similar for many Ras small molecule inhibitors, which highlights the challenge of finding a
potent Ras inhibtors given the strong Ras-effector binding affinity.
ZCL278 was intended to be a CDC42-GEF complex formation inhibitor, more specifically,
CDC42-ITSN1 complex inhibitor. However, it was used in our lab to influence the CDC42-ACK
complex formation based on the GTPase-effector interaction inhibition strategic approach.
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ZCL278 as our data show interfered with CDC42-ACK interaction and modified CDC42 and
CDC42F28L structures upon binding, which suggests that ZCL278 must be investigated on more
effector proteins like Wasp and PAK, and regulatory proteins like GEFs and GAPs to gain more
detailed information related to its selectivity and potency.
The in vitro binding assay data show that ZCL278 caused about 5 % decrease in CDC42-ACK
binding. This is not much but promising given CDC42 binds ACK with nanomolar affinity and
ZCL278 with micromolar affinity. Moreover, given the concentration of CDC42 used in the
experiment (200 µM) was much higher compared to that of the ZCL278 (50 µM), a 5% decrease
in the binding is significant. ZCL278 caused approximately a tenfold increase in the Kd values in
fluorescence spectroscopy (FS) and ITC experiments. For difficulties associated with proteinprotein interactions and protein-protein-small molecule interactions such as small molecule’s
insolubility in protein solvent, protein aggregation in small molecule solvent, addition of
disulfide bond breaker to optimize binding which in turn may interfere with the complex
formation and even changes the solution pH, it was particularly hard to determine accurately the
Kd values from FS and ITC. Nonetheless, the Kd values from our FS and ITC are close enough
and are obtained from triplicate experiments which increase our data reliability. Consequently,
improvements can be made on ZCL278 by making it more hydrophilic so that binding
experiments involving ZCL278 can be done in an environment more like the cytoplasmic
environment.
CDC42-ACK interaction is specifically determined by these seven residues, Ala41, Val42,
Thr43, Gly47, Thr52, Phe56, and Leu174, with Ala41, Val42, Thr43, Gly47 in the switch I
region [9]. ZCL278 was predicted to make H-bonds with Thr35, Asn39, and Ap57 of CDC42
(figure 6) and hydrophobic interactions with Val36 and Ph56. ZCL278 most likely interfered
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with CDC42-ACK interaction by making H-bonds with Thr35 and Thr43 and hydrophobic bonds
with Ala41, Val42, Gly47 in the switch I, which in turn impeded the CDC42-ACK binding
interaction.
More investigative work on ZCL278 including NMR spectroscopy will be paramount in
unveiling molecular details explaining ZCL278 interference with CDC42-ACK interactions.

Figure 6. Prediction of intermolecular interactions between ZCL278 and CDC42.
CD spectroscopy data show that ZCL278 upon binding to CDC42 and CDC42F28L changed
their secondary structure dominated by alpha helix into a random coil. The Conformational
modification may be due mostly likely to the H—bond interactions between CDC42 Thr35 and
ZCL278 since Thr35 plays a key role in CDC42 conformational stability. Moreover, through
hydrophobic interaction between CDC42 Ph28 and ZCL278, ZCL278 can alter the 3D structure
of CDC42 since Phe28 contribution to CDC42 overall structural stability is crucial and is done
via hydrophobic interaction between CDC42 Phe28 and the guanine ring of the nucleotide.
ZCL278 through its interaction with Phe28, Thr35, Thr43, Ala41, Val42, Gly47, shields the
switch I particularly Thr35 which is structurally very important for CDC42 stability which made
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it more thermally stable as indicated by the DSC data. Heat- and urea-induced denaturation
based on CD spectroscopy did not show much ZCL278 influence on the CDC42 and
CDC42F28L denaturation except for a two-step urea-induced denaturation of CDC42F28L
compared to a three-step urea-induced denaturation for CDC42. More investigation needs to be
conducted to shed more light on this.
CDC42 and CDC42F28L intrinsic nucleotide exchange did not show any difference in the
absence or presence of ZCL278; this is due mostly to the fact that ZCL278 binds in the switch I
which plays very little role in nucleotide exchange. Targeting signaling pathways modulated by
Rho family members has received increasingly much attention in drug discovery since this
approach has potential applications not only in cancer but also in neurodegenerative [10-12] and
infectious diseases [13]. There exist several ways in which inhibition of pathways controlled by
CDC42 has been approached, and one of them consists of targeting the CDC42-GEF interface,
and the complex that has been targeted the most is the CDC42-Intersectin complex (ITSN1).
ITSN1 is a CDC42 specific GEF [14,15] which is among the several RhoGEFs that are
frequently mutated in some types of cancer [16,19]. ZCL278 was docked into the ITSN1 binding
groove of CDC42 and showed promising results in in vitro studies with its anticancer properties
[20], and research conducted in our lab suggests that ZCL278 interfered with CDC42-ACK
direct interaction. Nonetheless, ZCL278 suffers from several disadvantages: 1) ZCL278 was
shown to be a partial agonist of CDC42 under certain circumstances; 2) ACK binds CDC42 with
nanomolar affinity while ZCL278 binds CDC42 with micromolar affinity; consequently, the
amount of ZCL278 sufficient to competitively prevent ACK or any other effector proteins from
binding CDC42 will be probably too high and might even be cytotoxic; 3) ZCL278 is highly
hydrophobic and very membrane-permeable, which is a poor feature for a drug candidate
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according to the Lipinski’s rules [18]. The discovery of the ZCL small molecule family has led
to another SMI called ZCL367 which had more selectivity potency towards CDC42 (IC50 =
0.098 μM) than ZCL278 [2].
ZCL367 was shown to inhibit migration and proliferation in lung and prostate cancer driven by
EGFR and Ras [2]. Moreover, a lung cancer xenograft mouse model treated with ZCL367
displayed decreased tumor growth [2]. Overall, the discovery of the ZCL SMI family has shed
more light on the Ras-related drug discovery area, particularly on SMIs targeting CDC42. It has
shown once again the structural and biological challenge faced in Ras-related proteins
therapeutic research [2]. With more research being done in Ras-driven cancer drug discovery, we
hope that the wealth of data being yearly published will contribute to the development of more
potent SMIs with high selectivity for individual Ras family members which will help tackle
cancer more drastically.
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CHAPTER FIVE: Experimental issues and solutions
Purification of a 4-KDa peptide: Problems and solution
ACK1, also known as TNK2, is a 120 KDa protein consisting of multiple domains including an a
SH3 and CRIB (CDC42-Rac interactive binding) domain [1]. This CRIB domain is commonly
shared among the CDC42 downstream effectors including members of the PAK family, and the
ACKs. CDC42 binds to the CRIB domain through the switch I and activates ACK1, which is one
of the three known ways ACK1 is activated [2]. Human ACK1 is majorly different from
bacterial ACK1 and purifying a biologically active ACK1 in E coli is simply impossible not only
for the difficulties encountered when purifying such a big protein from E coli since an affinity
tag would have to be attached to its end for purification purposes, but also for the complicated
post-translational modifications ACK1 is subject to once synthesized [3]. A simple way to
express and conveniently purify ACK1 is to express the domain of interest (CRIB domain) and
attach a GTS tag at its end. Attaching a GST tag not only helps solubilize the peptide [4], but it
allows purification using a GST affinity column as well. However, this GST tag can create
potential problems when it is time to remove it with thrombin and to separate the cleaved ACK
from the cleaved GST for downstream experiments. And this was where the most problems were
encountered. The thrombin cleavage was always successful; however, it was always difficult to
obtain ACK sample without some remaining GST, which would end up negatively influencing
downstream experiments. And even if it was thought that ACK was present in the sample, seeing
it on the gel was a headache since ACK is a very small peptide that is barely seen on a gel even
at 15% acrylamide. After many attempts trying to separate the thrombin-cleaved products using
affinity chromatography with the GST tag, it was decided that it could be easier to use size
exclusion chromatography.
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After many attempts, it was found that 1) the ACK is quickly diluted once loaded on the size
exclusion column, 2) the presence of just one tryptophan residue in ACK caused the UV signal
on the FPLC machine to be barely visible. Therefore, another method had to be found to
successfully separate the cleaved GST tag from cleaved ACK and to see the 4-KDa ACK on the
SDS-PAGE. That is when a method developed in Dr Kumar’s and our lab significantly changed
everything. This method is referred to as “heat treatment”; it consists of heating the thrombincleaved products up to 80 °C [3]. This high temperature causes the GST tag to aggregate while
the peptide, due to its high thermal stability, stays in its soluble state. Then, the sample is
centrifuged twice, the pellet is disposed of, and the supernatant which contains the soluble ACK
is carefully removed and placed in a new tube. A tris-tricine gel is run to better visualize the
peptide on the gel [4,5]. The heat treatment has proved itself to the best solution to purify ACK.
Tris-tricin gel was also very helpful since I just could not see my peptide on the gel unless tristricine gel was used.
In vitro binding assay: Problems and solution
An in vitro binding assay is an affinity-based assay which consists of binding either two purified
proteins together or two proteins from a crude protein lysate. The protein-protein complex is then
purified via affinity-based purification since one of the proteins bound together carries an affinity
tag. This technique is used to determine the binding interaction between two proteins. Our in
vitro binding assay was done between purified GSTACK and CDC42. The issues that were
encountered the most with that essay was that it was always hard to see CDC42 on the SDSPAGE since not all the CDC42 bound to GSTACK, and the amount that bound was almost
always diluted during elution.
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This dilution issue was even worse when trying to use size exclusion chromatography to solve
this problem since size exclusion chromatography, due to the size of the column (120 mL) is
notorious for extreme sample dilution, leading to huge loss of protein. To circumvent this
problem, it was decided to concentrate the eluates which contained the GSTACK-CDC42
complex, but due to long periods of centrifuging, much of the protein was lost, and nothing could
be seen on the gel. Another technique that successfully helped was the “TCA precipitation”,
which consists of aggregating and precipitating the GSTACK-CDC42 complex using 10%
Trichloroacetic acid (TCA) [6]. The precipitated complex is then washed with acetone to remove
any remaining TCA and an appropriate amount of 8M urea and sample dye were added to the
precipitate which was then heated for 1-3 minutes and was loaded on SDS-PAGE.
Isothermal titration calorimetry: Problems and solution
ITC is a technique used to quantitatively study biomolecular interactions. It consists of binding
two biomolecules where one is placed in the syringe and the other one in the cell. It operates by
measuring the amount of heat released or absorbed during the binding experiment. By measuring
the heat transfer, ITC provides the thermodynamic profile of the molecular interaction consisting
of the binding constants (Kd), reaction stoichiometry (n), enthalpy (∆H) and entropy (ΔS) [7].
There can be multiple sources of heat in an ITC: one source of heat is dilution. Whenever there is
dilution, there also heat that is released which comes from the ionic bonds destruction and Hbonds formation between the solute and water since most if not all ITC experiments are
conducted in aqueous solutions. Another source of heat is the binding interaction between the
two molecules being studied. This heat results from the intermolecular and atomic
rearrangements due to conformation change that occurs upon binding of the molecules.
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Based on these heat sources, the more molecules there are in the cell, the more heat sources there
are, the harder it is going to be to calculate the actual heat coming from the binding of the two
molecules of interest. Our ITC experiment involved ACK, CDC42, DMSO, TCEP, so there were
four different molecules in our ITC cell that were individually generating dilution heat and
possibly binding heat, and due to storage and cost reduction purposes, it was unsound to add the
DMSO and the TCEP to the working 1-Liter dialysis buffer. Therefore, DMSO and TCEP were
added by pipetting the appropriate amounts of DSMO and TCEP directly to the samples to
prevent buffer mismatch and due to inaccuracy associated with pipetting small volumes, it was
very difficult to match the buffer contents in the syringe and the cell, and that was the main
source of our issues. Another potential source of issues was the fact that DMSO is very reactive
and tends to react with buffer components, hence causes binding heat generation [8]. It was also
reported that DMSO significantly decreased binding affinity when used in binding interaction
[9]. Consistent with this finding, it was also reported in protein characterization studies, that the
presence of DMSO, even when used at low percentage, caused drastic differences in proteins
behaviors, and altered the binding affinities of binding interactions [10]. Another problem was
the addition of TCEP, a disulfide bond breaker, to prevent dimerization induced by concentrated
ACK. This component significantly changed the pH of buffers which led to a buffer mismatch.
The way to circumvent this problem is to add the TCEP in the dialysis buffer, but this is not cost
effective since TCEP is relatively expensive and to reach the appropriate concentration (5 mM)
in a one-liter dialysis buffer, you have to add almost the entire content of the bottle. At best, we
ended up having consistent data from our ITC experiments conducted in triplicate, but it is
essential that these data be interpreted and understood in the context of these experiments and the
potential sources of inaccuracy that were nevertheless necessary for this experiment to
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successfully take place. Some of these issues were successfully dealt with; for instance, dilution
heat inaccuracy was significantly minimized by dialyzing both proteins in the same buffer and by
diluting ZCL278 stock solution (dissolved in 100% DMSO) in the working dialysis buffer.
Nonetheless, the heat generated by the promiscuous binding of DMSO to the buffer salts and the
heat from the binding of TCEP to ACK S-S bonds were hard to account for. This can be seen in
the shift of the baseline of the binding isotherm. It was speculated that this baseline shift could be
fixed by increasing the delay time between injections or at least the first six injections, but this
never worked, but can still be tried in future studies in similar scenarios. It is always
recommended to run control experiments by removing one or more components of the sample
and do buffer subtraction. However, even when one of these components is removed, at least two
more components remain in the sample, and are interacting with each other, which greatly
increased the complication level of the experiment.
2D NMR spectroscopy: Problems and solution
NMR spectroscopy, in the field of protein NMR spectroscopy, is used to collect data about the
structure and the dynamics of proteins. Protein NMR spectroscopy research involves multiple
phases including expressing your protein of interest in a medium (M9) that will allow the
incorporation of isotope in the protein of interest, in our case it was the N15 isotope, purifying
the N15-labeled CDC42, preparing the sample in the correct buffer, collecting the data, and
interpreting the data.
In a protein NMR spectroscopy, problems can arise at any of the phases of the experiment. The
problems that were encountered in our case were mostly at the protein expression level and at the
measurement level.

114

The yield of CDC42 in E. coli was always low in the M9 media since it is not as rich as other
media like LB. So doing large scale production (up to 10 Liters) of the labeled protein was
almost a necessity. It is important to note at least in my case, that the cells grew as fast as they
did for expression done in LB media. The problem was mainly the low yield which basically
impeded progress in the NMR work. But data were still gathered since we were using the Bruker
700 MHZ magnet probe (figure 1) Things worsened when the 700 MHZ-magnet probe could not
be used any more, and since we started using a Bruker 500 MHZ, a concentration of 0.3-0.5 mM
was needed. This was a major problem since it was never easy to get to such concentration. And
the few times, we got it, the protein ended up aggregating (figure 2). I speculated that one way to
solve this problem was to express massively enough protein so a desired concentration can be
achieved in enough volume to prevent aggregation. This plan was being pursued until the 500
MHZ magnet broke down. So whether or not it would have worked remains unknown.
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